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Bleeding following trauma is exacerbated by coagulopathy and is a major cause for 
morbidity and mortality worldwide. The mechanisms influencing coagulopathy are not 
clear and require further exploration. A large pragmatic trial showed survival benefit from 
use of antifibrinolytics, suggesting fibrinolysis as a major component of coagulopathy. The 
overall aim of this work is to examine the incidence of fibrinolysis and magnitude of its 
activation in trauma, the protein mechanisms that may dominate in its modulation and to 
explore whether other coagulopathies may be important in trauma. 
A prospective cohort study of 325 injured trauma patients was carried out. Bloods samples 
were collected on arrival to ED and data collected on injury characteristics, demographics, 
blood component therapy and outcomes. An extension to the study included over 1500 
patients recruited from 6 European centres in the same manner. 
Only 5% of patients showed evidence of ROTEM Lysis, however, 59% of patients had 
evidence of fibrinolytic activation (FA) in that they had PAP levels over 1500 mcg/L. FA 
correlated with severity of head, chest and extremity trauma. Having FA conferred a 
significantly higher chance of needing blood or blood products, having septic complications 
and longer hospital stay as well as significantly increased mortality compared to those with 
no FA. 
High levels of PAI-1 were found to be associated with lower levels of FA even when tPA was 
high. High levels of circulating TAFI or TAFIa were not associated with reduced markers of 
fibrinolysis suggesting they don’t play a role in modulation. FXI depletion was associated 
with higher FA but its mechanism of action is unclear.   
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Hierarchical clustering was successfully used to classify 1229 patients with a biological 
dataset of 21 variables into 6 distinct groups. These showed predominantly fibrinolytic 
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1.1 Global burden of trauma 
Trauma is an important cause of mortality worldwide. It is estimated that, globally, 4.8 
million people died due to “injury”, in the year 2013(1). This included transport injuries as 
well as accidental and non-accidental injury.  Although this is receding in some parts of the 
world, traumatic injuries still contribute as a significant proportion of mortalities 
worldwide. This is particularly the case in the younger population.  Amongst the age groups 
15-19 and 20-24, mortality from transport injuries alone formed the single highest 
proportion of deaths in 1990 and in 2010 amongst males(2). The global burden of disease 
study (GBD) also found that “road injury” was the eighth highest cause of death over all. 
This is important as it seems to affect younger age groups. Globally, trauma injuries 
represented the eighth highest cause of years of life lost (YLL), and YLL could be argued to 
be an even more significant measure than mortality alone. 
1.2 Trauma in a regional context 
In the United Kingdom in 2014, trauma related deaths were amongst the leading causes of 
mortality in those aged less than 50 years old(3), which reflects the global trend described 
in para 1.1 above. Since mortality from trauma predominantly affects younger age groups it 
also contributes significantly to loss of productivity in society. The YLL measure alone 
cannot relay the total human cost involved. Trauma will affect all socioeconomic 
backgrounds and families of those involved, a cost which may never be quantifiable.  Those 
that survive traumatic injuries may suffer temporary or permanent disability, thereby 
contributing further to the personal and financial cost and productivity loss to society. 
1.3 Temporal distribution of mortality in trauma 
Deaths that occur in trauma appear to do so in a multi-modal distribution.  These have 
been broadly classified historically into immediate, early and late deaths(4,5).  Although 
some changes in timing and distribution of deaths has occurred since implementation of 
modern trauma systems, the overall causes and distribution are relatively unchanged(6).   
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Immediate deaths have been described as those occurring within an hour of injury.  These 
are largely unavoidable deaths due to massive neurological or cardiac and great vessel 
injuries. Intervention strategies in this phase of mortality are centred on injury prevention 
and education.  
Late deaths are those that occur days or weeks after injury. These are generally as a result 
of sepsis, multi-organ failure and may be influenced by comorbid conditions as well as age. 
Essentially this can be seen as late physiological collapse.  Although there is a great deal of 
research in this area and some promising advances being made(7), much involving critical 
care specialists, it is a difficult and complex problem to address.  
Early deaths, on the other hand, have broadly speaking been thought of as those that might 
be potentially avoidable with advances in trauma management.  These could include 
improved pre-hospital recognition and management(8,9), better access to imaging of a 
higher quality and resolution(10), improved access to interventions such as surgery and 
interventional radiology and improved understanding and implementation of damage 
control resuscitation(11,12) and surgical protocols to name a few. These early deaths occur 
in the first few hours of injury. As these deaths have been labelled as possibly preventable, 
research has tended to focus on this phase of mortality to improve outcomes. The window 
to recognise and manage these patients early is small with some reports showing as little as 
a median of 1.6hrs from injury to death, and others showing mean time to death of about 6 
hours (13–15). 
1.4 Mode of death in trauma 
Two modes of death appear to predominate worldwide in this population irrespective of 
timing or indeed differences in mechanisms regionally. Neurological injury accounts for the 
majority of deaths in trauma. Pang et al have reported that as many as 72% of deaths occur 
as a result of brain injury(16) with mean rates being between 44 and 64%(17). These deaths 
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tend to occur in all time scales following trauma but the majority occur immediately or 
early(14,18). 
The second most common cause of death is haemorrhage or exsanguination. These 
historically accounted for up 40% of all deaths and around 50% of early deaths(18). In the 
context of modern trauma systems it is accepted that they account for up to between 15% 
and 28% of all trauma deaths(17). Exsanguination occurring as a result of heart or great 
vessel injury is, of course, most likely to be un-survivable. However, death due to 
exsanguination from sources other than those stated is deemed possibly preventable and 
therefore an important area of management that is always under scrutiny. Where bleeding 
is as a result of a single site of trauma or even defined penetrating injury, haemorrhage 
control may be, relatively speaking, achievable. Blunt trauma on the other hand poses a 
difficult challenge in achieving surgical control. Moreover, bleeding associated with blunt 
trauma can often be exacerbated by coagulopathy. Since this is ‘non-compressible’ 
bleeding, it makes it even more difficult to definitively control.  
1.5 Bleeding and coagulopathy in trauma 
Bleeding in trauma is compounded by coagulopathy. The term trauma induced 
coagulopathy (TIC) is given to coagulopathy that occurs after severe injury. This was 
historically thought to be due to a combination of dilution of clotting factors (from fluid or 
blood administration), consumption of factors, hypothermia and acidosis(19). These are all 
important mechanisms and certainly do contribute but appear to be only relevant in 
extremes of physiology(20) or perhaps in later stages of injury and resuscitation. The 
relevance of coagulopathy, however, cannot be underplayed. Where coagulopathy is 
present mortality is over three-fold higher(21,22) but importantly in this group multi-organ 
failure (MOF), intensive care unit (ICU) stay and overall hospital length of stay (LOS) are all 
also much higher(21) suggesting significant systemic derangements other than simply 
coagulopathy. Over the years further influences of TIC have been defined and begun to be 
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understood(Figure 1.1)(23). Of course like any disease or condition, co-morbidities and 
genetics will play a role in physiological response also, but these are outside our influence 
in emergent trauma management. In recent years the central area of trauma research has 
been acute traumatic coagulopathy (ATC). 
 
Figure 1.1  Drivers of trauma-induced coagulopathy(23) 
 
1.6 Acute traumatic coagulopathy        
The historical norms were challenged with the publication of the seminal paper by Brohi 
and colleagues in 2003(24). They showed that 25% of patients arriving in the emergency 
department (ED) already had established coagulopathy.  Other studies have corroborated 
these results(21,22) leading to increased interest and research into ATC and its 
mechanisms.  In the same study, notably, this coagulopathy was not associated with 
increased fluid administration (and therefore dilution).  Those that arrived with 
coagulopathy had a four-fold increase in mortality, and where this coagulopathy occurred 
in the presence of more severe injuries, measured by the injury severity score (ISS), 
conferred between 80-100% mortality (for ISS≥45). The mechanism for this was postulated 
to be a systemic anticoagulation mediated through the protein-C (PC) pathway. Thrombin 
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was thought to be diverted to binding soluble thrombomodulin (TM) and away from its 
usual role in converting fibrinogen to fibrin. This ‘thrombin switch’ was tested in 
prospective trials to determine the relationships and mechanisms involved. Indeed Brohi 
and colleagues, in further work, showed PC was significantly reduced in the presence of 
TM(25), suggesting PC was being converted to activated protein-C (aPC). But this only 
occurred when there was evidence of significant hypoperfusion, as evidenced by base 
deficit (BD). In fact, even where there was thrombin generation, TM levels were only high 
when BD was high. Coagulation was also measured in this study based on prothrombin 
time (PT) and partial thromboplastin time (PTT). Coagulopathy only occurred in these 
severe hypoperfusion states. This showed that there was adequate thrombin generation in 
these states, but the combination of thrombin generation and hypoperfusion lead to the 
coagulopathy. The coagulopathy itself could be caused by aPC blocking the cleavage of 




Figure 1.2 Thrombin-Thrombomodulin activating PC 
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Hyperfibrinolysis (HF) or pathological fibrinolysis has also been implicated in coagulopathy 
following trauma. D-Dimers levels have been shown to be raised significantly post trauma. 
This had previously been understood as disseminated intravascular coagulation (DIC)(27). 
Brohi et al also demonstrated rise in D-Dimer in those patients with low PC(25) certainly 
suggesting evidence for fibrinolysis. It has previously been described that aPC is an inhibitor 
of the control mechanisms for fibrinolysis mainly by inhibiting plasminogen activator 
inhibitor-1 (PAI-1)(28), and in certain conditions the affinity for aPC and PAI-1 increases 
dramatically(29). Indeed PAI-1 is reduced significantly with low PC levels in the above 
described situation also(25). This argument for a “thrombin switch” and PC mediated 
coagulopathy was consolidated when it was shown that PC levels fall as TM increases but 
also that fibrinogen levels are maintained with higher levels of TM(30). It was also 
demonstrated that tissue plasminogen activator (tPA) increases with worsening 
hypoperfusion but was also associated with lower PAI-1 levels. Evidence of fibrinolysis was 
demonstrated again with high D-Dimer in these patients. So as well as aPC curtailing 
coagulation upstream (Figure 1-2), it was also promoting fibrinolysis downstream by 
removing the inhibitors of plasminogen activation (Figure 1-3)(26). This coagulopathy and 
its clinical sequelae only occur in the presence of both tissue hypoperfusion and tissue 
injury(31). Until recently aPC could not be measured directly and so our assumptions have 
been based on the observations of PC. Cohen and colleagues(32) have further tested these 
hypotheses and developed an in house assay to measure aPC. Indeed, their work has 
shown that coagulopathy is only demonstrated in the presence of both hypoperfusion and 
injury corroborating earlier work by Frith and colleagues(31). This same subset of patients 
in their study showed high levels of aPC and low PC. Findings also confirmed low factor V 
and VIII activity in the presence of high aPC and indeed high levels of tPA and D-Dimer in 
the same patients, strengthening both parts of the hypothesised mechanism. 
The summarised putative model is therefore as follows; 
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1. Hypoperfusion (shock) and tissue injury result in release of TM and tPA (from 
endothelium) 
2. Thrombin is diverted to complex with TM, therefore also contributing to 
coagulopathy by not cleaving fibrinogen to make fibrin 
3. Thrombin-TM complex catalyses the conversion of PC to aPC 
Here two further possible mechanisms result in clinical coagulopathy; 
a) aPC curtailing thrombin generation through inhibition of factors V and VIII 
b) aPC inhibiting PAI-1 and therefore allowing the generated tPA to promote HF 
unchecked 
Which of these mechanisms are more influential is still under debate. Certainly they are all 







The Cochrane review of antifibrinolytics in elective surgery showed benefit by reduction of 
transfusion requirements(33) with no significant risk of venous thromboembolism (VTE). 
There is certainly some overlap in the insults which trauma patients suffer and elective 
surgery patients undergo during major surgery. This led to a large pragmatic randomised 
controlled trial (RCT) to assess the benefit of tranexamic acid (TXA) in trauma(34). The 
CRASH-2 trial found that there was significant reduction in relative risk death from all cause 
mortality as well as death from bleeding. On the face of it these data suggest that HF is a 
significant mechanism in ATC. After all, the previous work from various units has shown 
evidence of lysis as a phenotype in trauma patients. But the Crash-2 trial did raise some 
very important questions about HF. 
1.8 Diagnosis of coagulopathy 
An important issue that needs to be addressed in the current clinical practice is how we 
diagnose coagulopathy, particularly in the emergent setting. Once coagulopathy has been 
established its utility in managing therapy would then need review. The work mentioned to 
date has used PT and PTT to diagnose coagulopathy. Maegele and colleagues have also 
 






used low platelet counts in conjunction with PT(21). These tests have been useful as 
markers of coagulation for researchers after fact. In clinical practice however they are of 
questionable use in the emergent trauma patient for a number of reasons. It is also 
important to note that they were originally developed for completely different 
utility(35,36). Historically the threshold for coagulopathy has been PT ratio (PTr) of greater 
than 1.5. This appears to be an arbitrary figure and a review carried out by Frith and 
colleagues of 3,646 cases from a European multicentre study showed that mortality was 
more likely above PTr of just 1.2(31). This was much lower than previously considered. In 
fact other parameters supported this threshold being considered a true coagulopathy. Red 
blood cell (RBC) and fresh frozen plasma (FFP) requirements were also significantly higher 
with PTr >1.2 (figure 1.4). This certainly leads us to rethink how we use PT in discussing 
coagulopathy. Rather than a high threshold of 1.5 there seems to be a dose dependant 
relationship with outcomes, i.e. the more coagulopathic trauma patients are on arrival the 
worse the likely outcomes. 
 The threshold for PTr is important to appreciate but using PT as an adjunctive tool in 
resuscitation of exsanguinating acutely unwell trauma patients is still challenging. 
Davenport and colleagues(37) reported a median time of 78 minutes until the PTr was 
available to clinicians. In this cohort of 300 subjects the PTr became available in less than 
30 minutes on only two occasions.  This is clearly unacceptable as a tool in emergency care. 
 






They went on to assess a hand held point of care (POC) device for measuring PTr at the 
bedside. In non-coagulopathic subjects the POC device agreed with the lab in 99% of cases. 
However in coagulopathic subjects there was significant difference between the POC 
device and the lab standard resulting in the POC device giving a high false negative rate 
making it unacceptable. The main focus on this work was to test ROTEM in its detection 
rate for ATC. They described a threshold of clot amplitude measured at 5 minutes (CA5) of 
<36mm correlated with PTr >1.2. Significantly this threshold also predicted patients 
receiving RBCs and FFP at significantly higher rates. This work now provides a tool that can 
diagnose coagulopathy within 5 mins and predict transfusion requirements. Other centres 
have used ROTEM to diagnose coagulopathy(38). But they have also taken it to the next 
step and use it to guide management of coagulopathy. Their algorithms are based more on 
experience however than on current evidence which is unfortunately lacking. Nevertheless, 
using ROTEM and other viscoelastic tests (VCTs) maybe more accurate and timely than 
relying on PTr and conventional lab assays. 
1.8.1 Principles of viscoelastic tests to diagnose coagulopathy 
Viscoelastic tests have been described as far back as 1948(39). In the past 15 years or so 
they have come back into favour as a research and a diagnostic tool in haemostasis. They 
are utilised to assess and follow coagulopathy and bleeding in cardiac surgery(40), obstetric 
haemorrhage(41), liver transplantation(42) and of course trauma(37,43,44) to name but a 
few disciplines. There are two major proprietary tests available; TEG (Haemonetics 
Corporation, Braintree, MA, USA) and ROTEM (TEM International, GmbH, Munich, 
Germany). ROTEM is much more commonly in use in Europe where as TEG is much more 
common in the USA. The principles are broadly similar. Both VCTs measure the ‘elasticity’ 
or the ‘clot firmness’ of the blood as it goes from its liquid form to its semi solid form 
during coagulation. They do this under low shear stress conditions to give a graphical 
representation of coagulation and following this of fibrinolysis. Blood is added to a cup and 
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activators are added to speed up the process of coagulation. The cup is then mounted into 
a pin mechanism. The pin (in the case of ROTEM) or the cup (in the case of TEG) oscillates 
in the machine. As a clot begins to form between the cup and pin the elastic properties of 
the blood change and the resistance between the cup and pin in increased. The machine is 
able to measure this resistance or impedance and give us a digital readout. ROTEM displays 
this as a ‘thromboelastogram’ on the screen and also quantifies this output in various 
measures (Figure ROTEM and Table 1). Given that the test is performed on whole blood the 
resulting trace represents the balance between clotting and fibrinolysis at all times 
throughout the clotting process. It also reflects the contribution of platelets in coagulation. 
A number of specific assays are available and are each used to look at specific aspects of 
the clotting system: 
 ExTEM – Activated clotting via extrinsic pathway using tissue factor 
 InTEM – Activated clotting via intrinsic pathway using ellagic acid 
 FibTEM – Activated clotting via extrinsic pathway and platelets inhibited  (with 
cytochalasin-D)  to assess the contribution of fibrin polymerisation alone 
 




Standard nomenclature ROTEM parameters. (Modified from Tem International 
GmbH, Martin-Kollar-Strasse 13–15, 81829 München, Germany, 2014.) 
 ApTEM – Activated clotting via extrinsic pathway with antifibrinolytic added to 
assess the level of fibrinolysis (by comparing ApTEM and ExTEM)  
Table 1-1 Description of ROTEM reported parameters  
 
ROTEM Parameter Description Interpretation of parameter 
CT(seconds) 
Clotting time 
Time from start of sample run to 
appearance of first detectable clot 
(amplitude of 2mm) 
 
Initiation phase 
Lag-phase of thrombin generation 
(dependent on activity of 
coagulation factors) 
CFT(seconds) 
Clot formation time 
Time from CT until level of clot 
firmness reaches 20mm 
 
Amplification phase 
Initial clot strengthening by 
formation of fibrin fibres 
α-angle (degrees) 
Kinetics of clot development - angle 
between centre line and tangent to 




Maximum velocity of clot formation 
(dependent on platelet function and 
fibrin polymerisation) 
CA’x’ (mm) 
Clot amplitude at 
time ‘x’ 
Mechanical clot quality at fixed time 
point e.g. 10 minutes (CA10) 
 
Propagation phase 
Clot strength at fixed time point 
determined by platelets, fibrinogen 




Mechanical clot quality 
 
Maximal clot strength – determined 
by platelets, fibrinogen and Factor 




Clot amplitude at 90 minutes 
(max time) compared to MCF 
Clot termination 
Determined by amount of fibrinolysis 
 
 





The data acquired as a result of ROTEM can be potentially more useful than PT in an 
emergent setting for a number of reasons. 
When measuring PT or PTT we get a single figure as a result. In ROTEM the course of clot 
formation or ‘clot firmness’ can be followed until a designated time, which potentially gives 
us a lot more data. This, in theory, could be much more useful (but also more difficult to 
interpret). ROTEM could also be used as a true point of care test if correctly implemented. 
For example, at our institution a ROTEM machine is in the resuscitation bay in ED. A sample 
could be processed as soon as blood is available. Although ROTEM can be used to follow 
clotting activity for up to eight hours in a research setting, useful information could be 
derived within minutes of commencing analysis. This is of course much faster than lab PT in 
the real world(37). In addition, the information derived using the ExTEM and FibTEM tests 
in conjunction could be used to tailor blood component therapy(45). It should be stressed, 
however, that this specific practice is still awaiting validation and further trial evidence. A 
recent consensus conference (46) failed to arrive at firm conclusions on this point and were 
unable to recommend specific product therapy based on VCT parameters alone.   
1.9 Scope for further research 
Accepting Davenport’s work(37) the coagulopathy described thus far has been diagnosed 
on the basis of PT and PTT. These are tests that were designed historically for a completely 
different utility(35,36). They certainly are not directed at detecting fibrinolysis for example. 
Tests for fibrinolysis, such as euglobulin lysis time (ELT), do exist but these are generally 
difficult to carry out and need to be done in a closely controlled lab environment(47). 
Certainly they are not suitable for rapid evaluation of HF in an emergent setting or indeed 
in the presence of antifibrinolytics(48). VCTs such as ROTEM are still relatively rare in day to 
day clinical use in EDs. In some settings they have been used to detect HF by measuring the 
degree of lysis on ROTEM. A few small studies have published this data but these would 
suggest that the incidence of HF (measured by ROTEM) is extremely low. In fact it ranges 
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between 3% and 6% (43,49,50). This is in contrast to the incidence of coagulopathy 
measured by PT or PTT which has been shown to be around 25% to 34%(21,22,24). 
However even in those who present with coagulopathy based on PT there is evidence of 
fibrinolytic activation (FA) as evidenced by D-Dimer and tPA (30). These previous findings 
would suggest that FA is more prevalent than those exhibiting HF alone. Furthermore, the 
documented mortality in patients with HF by ROTEM is 80-100% (43). This does not 
correlate with mortality described in other studies where coagulopathy found on PT is 
much lower. In addition CRASH-2 showed a survival benefit of 9% in groups receiving TXA 
compared to those that didn’t. Again this is in contrast to the reports of HF by ROTEM 
which show that virtually nothing can reverse this coagulopathy and it inevitably leads to 
mortality. Despite the findings of CRASH-2 some centres still give antifibrinolytics only in 
response to ROTEM HF. CRASH-2 evidence would again suggest that FA is more prevalent 
than seen on ROTEM and these ROTEM-undetected cases would benefit from TXA.   
The exact mechanisms of HF in trauma also need further review. The role of PAI-1, 
Thrombin activatable fibrinolysis inhibitor (TAFI) and α-2-Antiplasmin (A2AP) needs to be 
adequately understood. Their relative contributions in the modulation of the fibrinolysis 




1.10 Aims of this body of work 
The aims of the work presented here are therefore as follows: 
1. To investigate the true prevalence of FA or HF in our trauma population 
2. To determine the ability of ROTEM to detect FA and/or HF in our trauma 
population 
3. To understand the relative contributions of the fibrinolysis pathway factors in 
modulation or control of fibrinolysis in trauma 
4. Use all of the above to understand better the mechanisms responsible in 
development of ATC 












2.1 Study Design and participants 
This thesis comprises a discrete body of work nested within a much larger ongoing research 
project originally based at the Royal London Hospital (Whitechapel, London, UK) (RLH) and 
The John Radcliffe Hospital (Oxford, UK). The ‘Activation of Coagulation and Inflammation 
in Trauma II’ (ACIT II) study originally received ethical approval in November 2007 from the 
East London and City Regional Ethics committee (07/Q0603/29) to recruit 500 patients. In 
June 2010 this was extended to allow 2800 patients in total. In 2013 the study was 
extended to 5000 subjects to be recruited from European and US partners. The European 
Community funded FP7 study entitled “Targeted Action for Curing Trauma Induced 
Coagulopathy” (TACTIC; project ID F3-2013-602771) now incorporates 6 European trauma 
receiving hospitals in Amsterdam, Cologne, Copenhagen, Oslo, London & Oxford. 
The study itself is an ongoing prospective observational cohort trial of trauma patients 
admitted to the above centres. I was part of the admission and recruitment team for the 
RLH. Patients were recruited on admission to the ED and followed up to discharge or day 
28 of admission. Blood samples were drawn on admission and analysed for various markers 
of coagulation as well as ROTEM. Data were collected on injury characteristics, patient 
demographics and admission physiology. Fluids and blood or blood products administered 
in the first 24 hours were noted. Specific Injury assessment was completed for each patient 
by our in house data collectors and scored based on abbreviated injury scores (AIS) 
categories which were used to give total Injury severity scores (ISS). For the first 28 days of 
admission, data were collected on organ injury, ventilation requirement, critical care stay 
and various other outcomes.    
2.1.1 Inclusion criteria 
All patients arriving in the ED that triggered trauma team activation were eligible for 
inclusion. The criteria at the RLH are as follows: 
 GCS<14 or RR<10 or >29 or Systolic BP<90 
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 Chest trauma with altered physiology 
 Person hit by train 
 Amputation proximal to wrist or ankle 
 Occupant ejected from vehicle 
 Fatality in same vehicle as occupant 
 Suspected pelvic fracture 
 Person trapped under vehicle 
 Suspected open or depressed skull fracture 
 Fall from >2 metres 
 Polytrauma with burns 
 Penetrating trauma (neck to groin or proximal to elbow/knee) 
 Explosions 
 Industrial accidents 
2.1.2 Exclusion criteria 
Exclusion criteria for recruiting patients were as detailed below. The majority of these were 
set up so that we only captured patients who would have ATC and no other extrinsic or 
acquired forms of pre-existing coagulopathy: 
 Age <16 years 
 Patients transferred from other hospitals 
 Patients who were already incarcerated prior to the presenting incident 
 Patients presenting more than two hours after time of injury 
 Patients who received more than 2,000 ml of intravenous fluids prior to arrival in 
the ED 
 Patients with burns >5% of their total body surface area 
 Patients taking anticoagulant medication other than aspirin 
 Patients with a known bleeding diathesis 
 Patients with moderate to severe liver disease (Child-Pugh classification B or C) 
2.2 Consent process  
Recruiting patients to this particular project proved an interesting challenge. Our interest in 
ATC means that we had to obtain blood samples at the earliest possible time following 
injury and not more than two hours afterwards. Severely injured trauma patients often 
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display a variable level of consciousness or are even unconscious and possibly intubated 
and ventilated (for the most severe injuries). Those that are awake and seem alert are 
nevertheless likely to be in a difficult state of mind following a significant psychologically 
challenging event as well as physical trauma. They may be in significant pain or discomfort. 
For these and other reasons they may not be in a position to have a useful conversation 
about medical trials and be able to understand the minutiae of the trial or the consent 
process. Indeed it may be totally inappropriate to approach this subject at the time. 
Nevertheless, in order to be able to gain useful information blood samples are required 
immediately on arrival at the hospital. Our ethics approval therefore allows us to recruit 
the subject into the trial and obtain blood samples with the agreement of the admitting 
trauma team leader. This is usually the ED consultant but could also be the registrar.  They 
are the ‘professional legal appointed representative’ (PLAR) for each patient at the time of 
admission. All the ED consultants were well versed on the protocol and study itself 
beforehand and were extremely supportive. Once the PLAR had given approval we could 
take blood samples and collect data as required based on our protocol. After this at the 
earliest possible stage (usually the next morning) if the patient is conscious and capable of 
having a conversation we would approach them about the trial and have a discussion as 
required. If they were then in a position to understand, they may then give or withhold 
consent to enter the trial. If they were unable to have a conversation or communicate 
clearly at this stage we would return daily until they were in a position to do so. For those 
patients that were very unwell and admitted to critical care requiring sedation or 
ventilation the relatives or next of kin were approached at the earliest possible time. In the 
context they are the ‘legally appointed representative’ (LAR). They are able to give or 
withhold assent on the patient’s behalf. Even if assent was obtained from the LAR we 
would still return on a regular basis to reassess the suitability for the patient themselves to 
give consent. In the event that the patient did not have capacity to give or withhold 
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consent and no LAR was forthcoming, Police and social service teams would attempt to 
look for relatives or next of kin on a daily basis until found. All these attempts whether 
successful or otherwise to obtain consent were logged in our consent database. All PLAR 
consents were copied into the patient notes and when consent or assent was completed by 
the patient or LAR these were also noted in medical notes.  
An overwhelming majority of patients and LARs agreed with no issues. This was predictable 
as this is an observational trial and, apart from having blood tests drawn, does not affect 
care in any way. At times in the department we were running other interventional trials 
also. If this was the case consent for both trials would be sought simultaneously. In the 
event that consent was withdrawn for the interventional trial, again, the vast majority of 
patients still gave consent for this observational cohort study.  
2.3 Blood sampling 
Blood samples were drawn on patient arrival in the ED (within in 20 minutes). The samples 
taken on admission were labelled ‘0’ hour samples. These were taken as the baseline 
samples. Following this, samples were also taken at 24 and 72 hours. In addition, for 
patients requiring blood transfusion, further samples were also taken following 4, 8 and 12 
units of red blood cells (RBCs). ACIT II was set up to investigate all aspects of TIC and 
outcomes in trauma. My work focusses on ATC and therefore I have only utilised the 0 hour 
sample. Therefore, I will hereafter discuss only the 0 hour sampling protocol. It should be 
noted, however, that the other time point or transfusion point sampling was carried out in 
a virtually identical manner with only minor changes.  
On arrival in the ED a blood sample was sent urgently for the clinical care and decision 
making of the patient. This included arterial or venous blood gas, full blood count (FBC), 
clotting screen, fibrinogen level, urea and electrolytes (U&E) and group and screen. In 
addition to this sample the research team member (myself or one of 5 other team 
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members on the research rota) would obtain a further 20-25 millilitres (mls) of blood from 
an easily accessible vessel. This was usually from the antecubital fossa or from a femoral 
vein. This sample was immediately placed into various sample vacutainers as per Table 1. 
 
  
Table 2-1  Summary of blood sample collection patient arrival in ED 
Type of vacutainer 
Blood Volume 
(mls) 
Reagent used as 
preservative 
Intended use 
Coagulation 4.5 x2 vials 
0.109 M buffered sodium 
citrate (3.2%) 
Coagulation proteins 
Coagulation 2.7 x 1 vial 
0.109 M buffered sodium 
citrate (3.2%) 
ROTEM 
Proteomics (P100) 6.5 x 1 vial Protease inhibitor 
Assay of unstable or 
novel proteins 
PAXgene (RNA) 2.5 x 1 vial RNA stabiliser 
RNA analysis (gene 
expression) 
 
     
2.4 Sample processing and storage 
All the samples were processed immediately on arrival in our near patient research lab in 
the trauma clinical academic unit (TCAU). This was located in the hospital itself and within 5 
minutes walk from the ED. Before 2012 the ROTEM samples were processed in the TCAU 
with the other samples. After 2012 a ROTEM machine was acquired by the ED and ROTEM 
samples were processed in the resuscitation bay in ED itself before processing other 
samples in the TCAU lab. The samples were processed by myself and the other research 
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fellows. We all underwent a period of training and shadowing more experienced research 
fellows before we were allowed to process samples without supervision in order to 
maintain consistent techniques and familiarise ourselves with the protocol. From 2013 
when the study was extended to our European collaborators, our standard operating 
procedures (SOP) were shared with them. Many of their research fellows came to London 
for a periods of training and shadowing in order to familiarise themselves with our protocol 
and to accurately duplicate it at their centres in order to maintain consistency and quality.  
2.4.1 Coagulation samples 
The 4.5ml coagulation tubes were centrifuged at 1760g for 10 minutes in a Clinispin 
Horizon 853VES Laboratory Centrifuge (Woodley Equipment Company Ltd, Bolton, UK). The 
top 2/3 of the plasma was removed from each tube and returned to the centrifuge for a 
further 10 minutes at 1760g. From the remaining single spun samples the top 0.5mls was 
aliquoted into a 0.6ml Cliklok microcentrifuge tube (Simport, Jencons, UK). The “buffy coat” 
and top layer of red cells were aliquoted into a 1.5ml Fisherbrand microcentrifuge tube 
(Fisher Scientific, UK). The original 2/3 of plasma, once double spun, was again aliquoted in 
0.5ml increments into 3 x 0.6 ml Cliklok microcentrifuge tubes. All of these microcentrifuge 
tube were labelled and barcoded and stored at -80oC in partitioned cardboard cryoboxes 
2.4.2 Proteomics P100 samples 
The P100 vacutainers were centrifuged using the same equipment at 2500g for 5 minutes 
to activate the mechanical filter. The resulting plasma was then aliquoted in 0.5ml samples 
into as many microcentrifuge vials as possible, usually between 6 and 8. All microcentrifuge 
tubes were labelled and barcoded and stored at -80oC in partitioned cardboard cryoboxes. 
2.4.3 PAXgene RNA 
These samples required no processing. They were simply labelled and stored at -20oC 




A summary of the SOP is given in figure 2.1. All the above samples were processed and 
stored in the freezers in the TCAU to minimise delay and sample deterioration. At regular 
intervals these samples were logged and then moved to the university campus long term 
storage facility. Temperature logs were maintained for all freezers in the TCAU for internal 
quality control. The long term storage freezers were maintained by the university and had 
regular internal and external quality control checks, monitoring and alarms if out of 
temperature range.  
 
2.5 ROTEM analysis 
Sample processing for ROTEM was carried out as per the standard automated electronic 
pipette program. Samples were run in all 4 available channels and data on ExTEM, InTEM, 
FibTEM and ApTEM were recorded. All ROTEM parameters, including those described in 
chapter 1 were saved for later analysis. The ROTEM Delta machines were located in the 
 
Figure 2.1 Standard operating procedure for sample processing 
 
Figure 2.2 Sample processing SOP. This SOP contains all the samples carried out as part of ACITII over the years. 




TCAU initially and this is where samples were processed. In 2012, the ED acquired a 
machine in the resuscitation bay and initial samples were processed here. The citrated 
sample collected in a vacutainer from the patient was placed into the ROTEM delta 
machine which kept the blood incubated at 37oC. The ROTEM reagents were removed from 
refrigerated storage and allowed to come up to room temperature for a period of 10 
minutes prior to use: STAR-TEM (recalcitrant), ExTEM(Thromboplastin), InTEM(Ellagic acid), 
FibTEM(cytochalasin-D) and ApTEM(aprotinin). The machine was set up to run all 4 tests 
and each test well was set up with cups and pins in readiness for the test. At the 
appropriate time point all test wells were incubated with 300ml of blood and the STAR-
TEM reagent. ExTEM, FibTEM and ApTEM were also incubated with the ExTEM reagent. 
The InTEM test well was incubated with InTEM reagent. The FibTEM and ApTEM then had 
their own reagents added. All tests were run for a period of 60 mins and all data was then 
recorded onto the machine. Data was downloaded every 1 – 2 weeks and stored on the 
university servers as a backup. The machines underwent a quality control test at regular 
intervals and if these showed any issues the machine use was suspended and maintenance 
procedures were undertaken. There were 3 machines in our TCAU (in addition to the later 
machine in ED). If machines had to be taken offline or if more than 1 patient sample 
needed to be analysed there was sufficient redundancy to continue sample processing 
uninterrupted. The coefficient of variation data for ROTEM is given in table 2-2. These data 
are provided by (GmbH, Munich, Germany) and are similar to externally validated 
sources(51,52) 
 
Table 2-2 Coefficients of variation for ROTEM parameters (%) 
Precision CT CFT Alpha angle CA10 MCF 
Intra-assay 6 8 1 2 3 




2.6 Coagulation sample assays 
Where automated high volume sample processing capability existed for certain coagulation 
factors these were assayed by our main haematology lab using a Sysmex CS2100i analyser 
(Sysmex UK LTD, Milton Keynes, UK ) using Siemens reagents(Siemens AG, Germany). The 
remainder of assays were completed manually in the form of enzyme linked 
immunoabsorbent assay (ELISAs). All the coagulation sample assays were conducted on the 
double spun (i.e. platelet depleted) plasma from the process described in section 2.4.1 of 
this chapter. 
2.6.1 Sysmex automated system analyser    
Samples assayed by our Haematology lab included PT/ International normalised ration (INR), 
PTT and its ratio, Fibrinogen (Fg), Factor II, Factor V, Factor VII, Factor VIII, Factor IX, Factor X, Factor 
XI, Factor XIII, Von Willebrand factor Antigen (VWF:Ag), Antithrombin (AT), Protein C (PC), Free 
Protein S Antigen (PS), Soluble Fibrin Monomer Complexes (SFMCs), A2AP and D-Dimer. The specific 
methods, reference ranges and variability is summarised in table 2-3. It is important to note that 
the tests for the numbered coagulation factors ie; II, V, VII, IX, X, XI, and XIII measure 
activity rather than concentration. The sample processing was carried out in 2 main 
batches. The first batch of samples was from the RLH only. This batch includes up to patient 
number 324 in our recruitment database. Samples were subsequently processed in a 
second much bigger batch to include all other samples. The 2 batches had marginally 
different references ranges and both of these are given here. It is notable, however, that 
the variability is still the same and in fact the means in the references ranges are identical 
in many cases. In the remainder the variation is negligible. 
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PT 9.4-12.4 9.4-12.2 secs 
Siemens Innovin Sysmex UK Clotting 1.3% 2.0% 
INR 0.9-1.1 0.9-1.1 ratio 
APTT 21-31 21-31 secs 
Siemens Actin FS Sysmex UK Clotting 4% 4% 
APTT ratio 0.8-1.2 0.8-1.2 Ratio 
Fibrinogen 1.50-4.50 1.56 – 4.0 g/l Siemens Thrombin Sysmex UK Clauss 5.9% 2.3% 
Factor II 78-117 70 – 146 iu/dL 
Siemens Innovin and Siemens Factor 
II deficient plasma 
Sysmex UK Clotting by multi-dilution analysis 2% 7% 
Factor V 66-114 62 – 150 iu/dL 
Siemens Innovin and Siemens Factor 
V deficient plasma 
Sysmex UK Clotting by multi-dilution analysis 2% 7% 
Factor VII 50-150 67 – 143 iu/dL 
Siemens Innovin and Siemens Factor 
VII deficient plasma 
Sysmex UK Clotting by multi-dilution analysis 2% 7% 
Factor VIII 52-153 52 – 153 iu/dL 
Siemens Actin FS and Siemens Factor 
VIII deficient plasma 
Sysmex UK Clotting by multi-dilution analysis 2% 7% 
Factor IX 58-138 58 – 138 iu/dL 
Siemens Actin FS and Siemens Factor 
IX deficient plasma 
Sysmex UK Clotting by multi-dilution analysis 2% 7% 
Factor X 50-150 65 – 152 iu/dL 
Siemens Innovin and Siemens Factor 
X deficient plasma 
Sysmex UK Clotting by multi-dilution analysis 2% 7% 
Factor XI 58-148 58 – 148 iu/dL 
Siemens Actin FS and Siemens Factor 
XI deficient plasma 
Sysmex UK Clotting by multi-dilution analysis 2% 7% 
Factor XIII 70-14 55 – 155 iu/dL Siemens Berichrom F XIII Sysmex UK Chromogenic method 5% 6% 
Von Willebrand 
Antigen 
50-160 50 – 156 iu/dL Siemens vWF Ag Sysmex UK Latex immunoassay 1.4% 0.9% 
Antithrombin 81-119 81 – 119 iu/dL 
Siemens Berichrom Antithrombin III 
(A) 
Sysmex UK Chromogenic 1.3% 4.6% 
Protein C 72-162 72 – 162 iu/dL Siemens Berichrom Protein C Sysmex UK Chromogenic 1.3% 1.9% 
Free Protein S 
Antigen 
62-120 60 – 139 iu/dL Stago Liatest Free Protein S 
Diagnostica 
Stago 
Latex immunoassay 2.4% 2.6% 
2-antiplasmin 76-126 68 – 136 iu/dL Siemens Berichrom 2-antiplasmin Sysmex UK Chromogenic 0.5% 3.2% 
Soluble Fibrin 
Monomer Complexes 
<6 <6 g/mL Stago Liatest Fibrin Monomer 
Diagnostica 
Stago 
Latex immunoassay 2.5% 3.6% 
D-Dimer <550 0 – 440 ng/mL Siemens Innovance D-Dimer Sysmex UK Latex immunoassay 4.1% 4.3% 
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2.6.2 Coagulation sample ELISAs 
Samples assayed in our own lab as ELISAs included tPA,  Prothrombin fragments 1+2 
(PF1+2), Thrombomodulin (TM), Plasmin anti plasmin complex (PAP), Plasminogen 
activator inhibitor-1 (PAI-1), Thrombin activatable Fibrinolysis inhibitor (TAFI) and activated 
Thrombin activatable Fibrinolysis inhibitor (TAFIa). All ELISAs were carried out by 4 trained 
staff including myself under the supervision of our laboratory manager. Assays were 
completed as per the instructions for each test with no deviation. Where tests were above 
or below detection thresholds and we had further sample available, repeat assays were 
carried out with sample diluted further to allow detection within the range of the ELISAs. A 
summary of the ELISAs used is given in table 2-4 below. Of note the Thrombomodulin ELISA 
was first run using the commercially available kit provided by Diagnostica Stago (Asniers-
Surs-Seine, France). However on the second batch of testing the Stago ELISA kit was no 
longer in production and an alternative had to be sought. The second batch of tests 
(beyond RLH pt number 324) was run using the ELISA kit from Abcam (Cambridge, UK). 
Both ELISAs are shown in the table separately. 





















































PF 1+2 69-229 69-229 pmol/L 
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All ELISAs were carried out in the Queen Mary University Blizzard Labs. Common 
equipment in all tests were the multipipette used manually and an auto strip ELx50 plate 
washer (BioTek, Winooski, USA). 
2.6.3 Data Acquisition 
All ELISA data were collected as absorbance in duplicate at the suggested light spectrum 
length on a SIAFR Synergy HT plate reader (BioTek, Winooski, USA) using KC4 v3.4 software, 
plotted against the dose and a standard curve fitted by linear regression analysis using 
GraphPad Prism program version 4.0 (GraphPad Software Inc., San Diego California USA) in 
accordance with the manufacturers’ and GraphPad Prism Instruction Manual. Mean 
absorbance was converted to the relevant units (e.g. pmol/L) of the given coagulation 
protein using linear regression. 
2.7 Data Collection 
2.7.1 Patient demographics and injury characteristics 
At the time of blood sample collection and recruitment, heart rate, systolic blood pressure 
(SBP), respiratory rate, Glasgow coma score (GCS), temperature, time of injury and time of 
blood draw were recorded. Full patient demographics, mechanisms of injury, injury type 
and severity were collected from the RLH trauma registry as soon as available. Injuries were 
scored and classified according to AIS to work out a composite ISS(53) .  
2.7.2 Fluid therapy in the first 24 hours 
All intravenous (IV) fluid therapy as well as blood or blood product transfusions were 
recorded for the first 24 hours of admission. These were broken down into crystalloids, 




2.7.3 Outcomes measures 
Outcome measures were collected including 28 day outcome (discharge or death), total 
LOS, critical care days, ventilator free days, vasopressor days and renal replacement 
therapy (RRT) days 
2.8 Statistical analysis 
All analysis was carried out using GraphPad Prism 4.0 (GraphPad Software Inc., La Jolla CA, 
US), Microsoft Excel 2010 (Microsoft Inc., Redmond WA, US) and MATLAB (Mathworks, 
Natick, MA, USA). Parametric data are expressed as mean ± standard deviation (SD) or 95% 
confidence intervals. Non parametric data are expressed as median and interquartile range. 
For comparison between two groups analysis was performed using two-tailed unequal 
variance student’s t test for and Mann-Whitney U for parametric data non-parametric data 
respectively. For more than two group comparison the Kruskal-Wallis test was used and no 
assumption was made about the normality of the groups. For analysis of contingency data, 
a 𝑥2 test for trend was used. A P-Value of <0.05 was used to represent statistical 
significance throughout this work.   
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  Chapter 3






Trauma is a global public health problem leading to millions of deaths a year. Forty per cent 
of trauma deaths are due to bleeding and occur in the first few hours after injury(18). 
Haemostatic dysfunction is common and up to 25% of severely injured trauma patients 
have an established coagulopathy when they arrive in the ED(24). This early coagulopathy 
is independently associated with mortality, increased transfusion requirements, organ 
injury, septic complications and critical care stays(25).  Understanding the aetiology of 
acute traumatic coagulopathy and all aspects of haemostatic dysfunction associated with 
trauma is a current imperative in the management of these patients. 
Fibrinolysis is known to occur during traumatic coagulopathy but the true incidence and 
magnitude of fibrinolytic activity (FA) in trauma has never been studied in detail(30).  
Screening laboratory tests of coagulation (e.g. PT, PTT) do not assess fibrinolysis and near 
patient global assays such as thromboelastometry are not in widespread routine use. The 
few small studies that have investigated the use of rotational thromboelastometry 
(ROTEM) in trauma suggest that the measure of FA used, known as ROTEM 
hyperfibrinolysis, is rare with an admission incidence of 3-6%(43,49,50).  However 
abnormal laboratory coagulation results are common in trauma patients and we have 
previously shown their association with an increased fibrinolytic potential(30).  This 
suggests the underlying incidence and magnitude of fibrinolysis may be more common 
than considered previously. 
Hyperfibrinolysis is classically defined as when fibrinolytic activity is potentially greater that 
fibrin formation, such that clot integrity is threatened.  Hyperfibrinolysis is identified on 
ROTEM when maximum lysis (ML) exceeds 15% of the maximum clot firmness(51).  
However there has never been an attempt to correlate this definition with classic 
laboratory tests of fibrinolysis. Trauma patients with ROTEM hyperfibrinolysis have 
mortality rates of 80-100%, even when treated(49). However, clinical trials of 
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antifibrinolytic therapy suggest that activation of fibrinolysis is more prevalent. Trauma 
patients randomised to tranexamic acid in the CRASH-2 trial had a 9% improved survival 
compared to those who received placebo(34).  Despite these findings some trauma units 
only administer antifibrinolytics if ‘ROTEM hyperfibrinolysis’ is present.   On the basis of the 
results from CRASH-2, we hypothesized that trauma patients have increased FA that is 
undetectable by ROTEM which might explain the benefit from tranexamic acid 
administration. 
The objectives of the current study were to determine the prevalence and severity of FA in 
trauma as measured by increases in plasmin generation, as measured by plasmin-
antiplasmin levels (PAP). Secondly we wished to determine the ability of the ROTEM to 
detect FA. Lastly we wished to assess whether FA was associated with the severity of 
injuries, admission physiology and clinical outcomes. 
3.2 Methods 
We conducted a prospective observational cohort study of trauma patients presenting to a 
single major trauma centre. The study was reviewed and approved by the UK Regional 
Ethics Committee. Between January 2007 and June 2009 all adult trauma patients (>15 
years) who met the local criteria for trauma team activation were eligible for enrolment 
into the study. Exclusion criteria were arrival in the ED >2 hours following injury; >2000ml 
intravenous fluid prehospital; transfer from another hospital and burns >5% total body 
surface area. Patients were retrospectively excluded if they declined to give consent to use 
research samples; were receiving anticoagulant medications (not including aspirin); had 
moderate or severe liver disease or a known bleeding diathesis.  
We categorized patients according to the degree of increased fibrinolytic activity based on 
the level of PAP complexes and ROTEM hyperfibrinolysis.  Expected normal values for PAP 
levels as given by the manufacturer were 120–700µg/L (2.5%-97.5% percentiles).  PAP 
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thresholds were arbitrarily set at approximately twice the upper limit of normal for 
moderate FA (>1500µg/L), in order to exclude minor elevations that might be expected in 
these patients. ROTEM hyperfibrinolysis was defined as ML >15%(51). 
Patterns of FA were classified as; 
 ‘Normal’ (PAP ≤ 1500 µg/L & ML <15%) 
 ‘Moderate’ with FA only (PAP >1500 µg/L & ML <15%) 
 ‘Severe’ with FA and ROTEM lysis (PAP >1500 µg/L & ML >15%) 
 ROTEM only lysis (PAP ≤ 1500 µg/L & ML >15%) 
A 20mL research sample of blood was drawn from either the femoral vein or antecubital 
fossa along with the standard trauma laboratory tests within 20 minutes of arrival in the 
ED. Blood for thromboelastometry analysis was drawn into a 2·7ml citrated vacutainer 
(0·109M buffered sodium citrate, 3·2% - Becton Dickinson, Plymouth, UK). Samples for PT 
were collected into 4·5ml glass vacutainers (0·109M buffered sodium citrate, 3·2% - Becton 
Dickinson, Plymouth, UK), volume 9:1. The PT was processed on the Sysmex CS2100i 
automated analyser. The sample for haemostatic assays was placed in a citrated tube and 
spun down within two hours of blood draw. First at 1750g for 10 minutes, the supernatant 
was then extracted and respun at 1750g for a further 10 minutes. The extracted plasma 
was stored in aliquots at -80°C freezer. Blood gas analysis for Base Deficit (BD) was 
performed simultaneously with the research sample collection. 
ROTEM samples were processed within one hour of blood draw at 37°C on a ROTEM delta 
instrument (TEM International GmbH, Munich, Germany) and all treating clinicians were 
blinded to the results. The methodology and the parameters of ROTEM have previously 
been described in detail(54) and in chapter 2.5 above.  Two separate ROTEM assays were 
performed for each patient, the EXTEM measuring tissue factor initiated clotting and the 
APTEM with the addition of an antifibrinolytic.  For the EXTEM, 20µl of 0.1M CaCl2 
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(STARTEM) and 20µl of tissue factor derived from rabbit brain were placed into the test 
cuvette after which 300µl of the blood sample was added. The APTEM test analysis was 
performed in the presence of 20µl aprotinin. Mild activation with tissue factor is performed 
to standardize the in vitro coagulation process and produce a more rapid result. All 
pipetting steps and the mixing of reagents with samples were guided by the electronic 
pipette program. Clot breakdown was determined by rate of maximum lysis (ML) during 60 
minute assay time for each sample analysed. Plasma activity levels of α2-antiplasmin 
(Siemens Berichrom 2-antiplasmin, Sysmex, UK) were assayed using a Sysmex CS2100i 
automated analyser. Latex immunoassays were used to quantify the levels of D-Dimer 
(Siemens Innovance D-Dimer, Sysmex, UK) also using Sysmex CS2100i automated analyser. 
Enzyme linked immunosorbant assays were used to quantify tissue plasminogen activator 
(tPA ; Asserachrom tPA,  Diagnostica Stago, France); plasmingen activator inhibitor- 1(PAI-
1; Asserachrom PAI-1, Diagnostica Stago, France); prothrombin fragments 1+2 (PF 1+2; 
Enzygnost F1+2 monoclonal, Siemens Healthcare Diagnostics, Germany); plasmin-α2-
antiplasmin complex (PAP; DRG PAP micro, Germany); thrombin activatable fibrinolysis 
inhibitor(TAFI; Asserachrom TAFI, Diagnostica Stago, France); and activated thrombin 
activatable fibrinolysis inhibitor(TAFIa; Asserachrom TAFIa, Diagnostica Stago, France) 
Data were collected prospectively on patient demographics, time of injury, mechanism 
(blunt or penetrating), prehospital fluid administration, time of arrival in the ED and 
baseline vital signs. Injury was classified using the ISS(53) as moderate (<16) severe (16-24) 
or critical (>24) trauma.  Arterial or venous blood gas base deficit was used a marker of 
tissue hypoperfusion. Patients were followed until hospital discharge or death. Outcome 
measures recorded were 28-day mortality, 28-day ventilator-free days and all transfusions 
required in the first 24 hours. 
52 
 
Normal-quantile plots were used to test for normal distribution in patients with mild 
injuries and no shock. Parametric data are expressed as mean (confidence intervals). For 
the parametric data two-group analysis was performed with a two tailed unequal variance 
Student’s t test. Injury severity and its components (AIS), ventilator free days and hospital 
length of stay were not normally distributed and expressed as median (interquartile range). 
For the non-parametric data, 1 way ANOVA (Kruskal-Wallis) was used for analysis.  
Univariate and multiple regression analyses were used to assess correlation. When 
analysing contingency data, χ2 test for trend was used. A p value of <0·05 was chosen to 
represent statistical significance throughout. 
3.3 Results 
Three hundred and twenty three trauma patients were eligible for enrolment into the 
study over an 18-month period. 4 subjects declined consent, 3 were discharged early with 
no contact details, 6 were unable to give consent and had no next of kin, 5 were unable to 
consent and their next of kin declined on their behalf and a further 2 patients were 
excluded due to protocol violation. Of the 303 remaining patients, 10 did not have ROTEM 
studies performed, 5 were unable to have ROTEM studies leaving 288 patients included in 
the study. Patient demographics and injury characteristics are shown in Table 3-1. The 
admission physiology and outcomes are summarised in Table 3-2. The rate of blunt trauma 
and mortality increased with the magnitude of lysis, all of those with severe lysis had 
suffered blunt trauma and carried a mortality of 40%. The admission temperature in all 





Table 3-1 Patient Demographics and Injury Characteristics 
Values are number (%), mean (confidence intervals) or percentage of patient group. ISS and AIS are given as median (interquartile range). ISS: Injury 
Severity Score, AIS: Abbreviated Injury Score. ‘*’ denotes p <0.05 vs Normal, ‘+’ denotes p<0.05 moderate vs severe lysis. 
 ALL PATIENTS NORMAL MODERATE SEVERE ROTEM LYSIS ONLY 
Number 303 100 (35%) 165 (57%) 15 (5.2%) 8 (2.7%) 
Age 37 (36-39) 32 (30-35) 40 (37-43)* 40 (33-47) 44(36-53) 
% Male 81.9 85.0 80.0 73.3 87.5 
Injuries      
% Blunt Trauma 79.5 63.0 88.5* 93.3* 50 
ISS 10 (4-25) 6 (1-10) 17 (9-28)* 25 (17-38)* 5 (2-9) 
% ISS >15 41.9 12.2 55.8* 86.7* 0 
AIS  Extremity 1 (0-3) 0 (0-2) 2 (0-3)* 3 (1-3)* 1 (0-2) 
AIS Thorax 0 (0-3) 0 (0-1) 2 (0-3)* 3 (0-5)* 0 (0-0) 








Table 3-2 Admission physiology and outcomes 
Values are mean (confidence intervals) or percentage of patient group. Ventilator free days and hospital stay are given as median (interquartile range).  
SBP: Systolic Blood Pressure, PT: Prothrombin Time, ROTEM CT: Clotting time on ROTEM, ROTEM CA5: clot amplitude at 5 minutes on ROTEM, PRBC: 
Packed Red Blood Cells, FFP: Fresh Frozen Plasma. ‘*’ denotes p <0.05 vs Normal, ‘+’ denotes p<0.05 moderate vs severe lysis. 
 ALL PATIENTS NORMAL MODERATE SEVERE ROTEM LYSIS ONLY 
Admission physiology      
Temperature(°C) 35.8(35.6-36.0) 36.0(35.8-36.2) 35.7(35.3-36.0) 35.1(34.0-36.3) 36.0(35.3-36.6) 
SBP (mmHg) 130 (127-133) 130 (125-136) 130 (125-136) 119 (100-138) 141 (128-155) 
Base Deficit (mmol/l) 2.4 (1.8-2.9) 0.5 (-0.1–1.1) 2.9 (2.1-3.7)* 8.6 (5.2-12.0)*+ 0 (-2.3-2.6) 
PT (seconds) 11.6 (11.5-11.8) 11.2 (11.1-11.4) 11.7 (11.5-12.0)* 13.6 (11.8-15.4)* 11.3 (10.8-11.7) 
% PT ratio >1.2 9.4 3.0 10.9* 40.0* 0.0 
ROTEM CT 70.0(64.8-75.1) 72.0(65.5-78.6) 67.4(59.6-75.1) 84.7(61.5-108.0) 69.9(44.0-95.7) 
ROTEM CA5 42 (41-43) 43 (41-45) 42 (41-43) 35 (30-41)*+ 41 (29-51) 
24-Hour transfusions      
PRBC  (units) 1.7 (0.6-2.7) 0.2 (0.0-0.7) 2.0 (1.3-2.7)* 6.5 (3.0-10.0)*+ 0 (0-0) 
FFP (units) 0.8 (0.1-1.5) 0.1 (0.0-0.9) 1.0 (0.6-1.4)* 2.9 (1.2-4.5)* 0 (0-0) 
Platelets (units) 0.2 (0.0-0.4) 0.0 (0.0-0.0) 0.2 (0.1-0.3)* 0.7 (0.3-1.0)*+ 0 (0-0) 
Cryoprecipitate (units) 0.2 (0.0-0.4) 0.0 (0.0-0.0) 0.2 (0.1-0.4)* 0.6 (0.2-1.0)* 0 (0-0) 
Outcomes      
28-day Mortality % 8.9 1.0 12.1* 40.0* 0.0 
28-day Ventilator-free days 28 (27-28) 28(28-28) 28 (27-28)* 28 (27-28) 28 (27-28) 
Hospital stay (survivors) 15 (12-18) 2 (1-6) 11 (4-25)* 26 (15-32)* 4 (1-9) 
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3.3.1 Rates of Fibrinolytic Activation and ROTEM lysis 
Fifteen of the patients (5%) had ROTEM hyperfibrinolysis, and of these four patients (1%) 
had a ML >50% (Figure 3.1A).   180 patients (59%) had evidence of FA in that they had PAP 
levels over 1500 µg/L. 165 patients (57%) had increased PAP levels (>1500µg/L) without 
ROTEM hyperfibrinolysis (Figure 3.1B).  Significant increases in ML occurred when PAP 
levels were above 20,000 µg/L (Figure 3.1C). When aprotinin was added in vitro to the 
plasma sample, there was an improvement in ML only in this group. Active fibrinolysis was 
evidenced in the moderate group by markedly increased D-Dimer levels (Table 3-3). 
Plasmin generation was associated with significantly increased fibrin breakdown as 
measured by D-Dimer production regardless of whether lysis was visible on 
thromboelastometry (Figure 3.1D). There was a ROTEM-only lysis group with 8 patients 
(2.7%) that showed no FA. They had low mean PAP levels (1011 µg/L) and no evidence of 
fibrin breakdown as characterised by D-Dimer (mean 865ng/mL). In fact this was lower 





        
 
   
 
     
Figure 3.1 Thromboelastometry underestimates the incidence and severity of fibrinolysis 
  
A: Incidence of hyperfibrinolysis as defined by functional lysis on ROTEM (ML) 
B: Incidence of moderate and severe hyperfibrinolysis (Normal: ROTEM ML<15% and PAP<1500µg/L; 
Moderate: ML<15% and PAP>1500µg/L; Severe: ML>15% and PAP>1500µg/L)  
C:  Functional clot lysis (dark bars) was only measureable with very high PAP levels (ML%: 
PAP<1500µg/L - 8.8% vs PAP>20,000µg/L - 30.3%). Functional clot lysis improvement with aprotinin 
(white bars) was only identified at high plasmin levels (%ML: PAP<1500 - 0.5% vs PAP >20,000µg/L - 
27.3%; *p<0·001 vs PAP<1500µg/L). 
D: D-Dimer levels were equivalent whether or not lysis was detected on thromboelastometry for 
given plasmin generation levels (D-Dimer: PAP 1500-20000 - ML≤15% 29,167 vs ML>15% 23,390 
p=0.85; PAP>20000 –ML≤15% 171,971 vs ML>15% 146,093 p=0.62;  *p<0.05 compared to 













































































Table 3-3 TEM and Coagulation factor assays 
Values are mean (confidence intervals). ML: maximum lysis. PAP: plasmin-antiplasmin complex (normal range 120-700 µg/L). tPA : tissue plasminogen 
activator (normal range 2–12 ng/mL). D-Dimer (normal range <550ng/mL). Antiplasmin (α2) (normal range 76-126 iu/dL). PAI-1: Plasminogen activator 
inhibitor-1 (normal range 4-43 ng/mL). PF1+2: prothrombin fragments 1+2(normal range 69-229 pmol/L). TAFI: thrombin activatable fibrinolysis inhibitor 
(normal range 7.6-10.6 µg/mL). TAFIa: activated thrombin activatable fibrinolysis inhibitor (normal range 8.53-22.07 ng/ml). ‘*’ p <0.05 vs Normal, ‘+’ 
denotes p<0.05 moderate vs severe lysis. 
  ALL PATIENTS NORMAL MODERATE SEVERE ROTEM LYSIS ONLY 
ML 9.4 (8.0-10.8) 8.1 (7.4-8.7) 6.6 (6.0-7.1)* 45.5 (28.0-63.0)*+ 18.4 (16.5-20.3)* 
PAP 4690 (3887-5494) 928 (862-993) 5844 (4835-6854)* 17503 (10502-24503)*+ 1011 (794-1227) 
tPA  11.8 (10.2-13.5) 8.0 (6.8-9.1) 12.4 (10.8-14.0)* 39.1 (14.5-63.7)* 8.3 (3.8-12.7) 
D-Dimer 30544 (22822-38266) 2576 (1727-3426) 38687 (30502-46872)* 88831 (31348-146315)* 865 (488-1243)* 
Antiplasmin 122.8 (119.6-126.1) 131.4 (127.6-135.2) 120.4 (116.0-125.0)* 86.7 (66.0-107.3)*+ 130.4 (119.9-141.0) 
PAI-1 32.7(28.0-37.4) 38.3(27.7-48.9) 29.6(24.6-34.6) 28.6(21.4-35.8) 43.7(0.1-87.4) 
       
PF1+2 1865 (1562-2168) 596 (489-703) 2314 (1911-2716)* 5062 (2546-7577)* 316 (234-399)* 
Fibrinogen 2.1 (2.0-2.1) 2.2 (2.1-2.3) 2.1 (1.9-2.1)* 1.5 (1.1-1.9)*+ 2.1 (1.7-2.4) 
       
TAFI 12.6 (12.2-13.0) 13.5 (12.9-14.1) 12.0 (11.5-12.5)* 10.6 (9.0-12.4)* 13.3 (11.1-15.3) 




3.3.2 Relationship to injury characteristics 
Increasing injury severity score was associated with increasing FA, as measured by both 
PAP levels and ML (Figure 3.2A).  However ROTEM ML increased only minimally, from 6% 
with ISS≤15 to 12% for ISS>24 (p=0·10). In contrast PAP levels rose just over 5-fold from 
2036µg/L (ISS≤15) to 10697µg/L (ISS>24, p<0·001).  90% of patients with an ISS>24 had PAP 
levels >1500µg/L, but in only 11·6%had ROTEM hyperfibrinolysis (Figure 3.2A), showing 
that PAP was more sensitive to injury severity than ROTEM.  In a multiple regression of all 
organ injuries, PAP levels correlated with the severity of head, chest and extremity trauma 
(p<0·001 all 3 regions; r2=0·28): whereas %ML was very weakly correlated with the severity 
of extremity injury only (p=0·008, r2=0·05).  PAP levels correlated with the degree of shock 
as well as injury severity (BD p<0·001; ISS p<0·001; r2=0·36, Figure 3.2B).  88% of patients 
with a BD >6mmol/l had moderate fibrinolysis compared to 58% of patients with BD 
<6mmol/l (p<0.0001, Figure 3.2C). D-Dimer levels were high even with relatively low levels 
of shock (Figure 3.2D).  ROTEM maximum lysis levels were not correlated with the degree 
of shock as measured by the base deficit or systolic blood pressure. Low SBP was also 
associated with increasing FA (Figure 3.2E) and 91% of patients with a SBP <90mmHg had 
moderate or worse FA compared to 59% with SBP >90mmHg (p =<0.0001, Figure 3.2F).  
Mild FA occurred at moderate levels of both injury severity and shock, whereas severe 
hyperfibrinolysis only occurred in association with the most severe extremity injuries. 
ROTEM-only lysis followed the same injury pattern as no lysis with low levels of shock and 




   
 
   
 
               
Figure 3.2 Fibrinolytic activation is associated with injury severity and the degree of shock 
A: Proportion of patients presenting with high ML and PAP levels by injury severity scores. %patients with overt 
fibrinolysis (ML>15%) rose slightly with injury severity (ISS <16: 5.8%, ISS 16-24: 10.0%, ISS>24: 11.6%, p >0.05), 
while %patients with PAP>1500µg/L rose substantially with injury severity (ISS <16: 43.8%, ISS 16-24: 87.5%, 
ISS>24: 90.9%, p <0.001) 
B: PAP levels increased with the degree of systemic hypoperfusion (*p <0.001 vs BD <3.0mmol/l).  
C: Proportion of patients presenting with high PAP (>1500µg/L) increased with systemic hypoperfusion (BD<3.0: 
55%, BD 3.1-6.0: 71%, BD 6.1-9.0: 93%, BD>9.0: 86%, P<0.001 vs BD <3.0mmol/l)  
D: D-Dimer levels increased significantly with increasing hypoperfusion. Even at moderate hypoperfusion (BD 
3.1-6.0: D-Dimer 49,387ng/mL) levels were very high and increased substantially as hypoperfusion increased 
(BD 6.1-9.0: D-Dimer 66,233ng/mL, BD>9.0: D-Dimer 86,892ng/mL p<0.001 vs BD <3.0mmol/l) 
E: PAP levels were inversely related to SBP. Even at borderline SBP, PAP levels were significantly higher and 
continue to rise as SBP falls (SBP >105mmHg: 3170µg/l; SBP 91-105mmHg: 6776µg/l; SBP 76-90mmHg: 
11029µg/l; SBP ≤75: 14,876 µg/l, p<0.001 vs SBP >105mmHg) 
F: Proportion of patients with high PAP (>1500µg/L) increases with falling blood pressure (SBP >105mmHg: 58%; 
SBP 91-105mmHg: 66%, SBP 76-90mmHg: 92%, SBP ≤75mmHg:  89%; p<0.0001 vs SBP >105). Values are % or 



































































































































3.3.3 Mechanisms of activation 
Both tPA and PAP levels were significantly incrementally elevated as expected in all those 
with FA (Table 3-3). Levels of PF1+2 (Table 3-3) also incremented in the same pattern as FA, 
suggesting that thrombin might be a key stimulator of tPA release from the endothelium. 
Levels of tPA correlated with hypoperfusion as well as injury severity (ISS: p=0·002; BD: 
p<0·001; r2=0·19). Severe FA was associated with massive tPA production and PAP levels 
such that there was significant consumption of antiplasmin (Figure 3.3A). Severe 
hyperfibrinolysis was only seen in association with α2-antiplasmin activity below 75iu/dL 
(Figure 3.3B).  However significant D-Dimer generation continued to occur whatever the 
level of α2-antiplasmin activity (up to 125iu/dL , Figure 3.3C). TAFI levels did not seem to 
strongly affect the regulation of fibrinolysis as D-Dimer levels were negatively correlated 
with TAFI levels and positively correlated with TAFIa levels (Figure 3.3D). ROTEM only lysis 





    
 
      
Figure 3.3 Mechanisms of activation of moderate and severe fibrinolysis  
A: Antiplasmin activity fell in Moderate fibrinolysis but was only 66% of normal in the Severe group (Normal 
131iu/dL; Moderate 120iu/dL; Severe 87iu/dL, *p<0.001 vs Normal). 
B: ROTEM hyperfibrinolysis was only seen when antiplasmin activity fell below 75iu/dL (%ML: AP 50-75iu/dL : 
23.1%, AP: 151-175iu/dL: 7.4%, *p<0.01 vs AP 151-175iu/dL). 
C: In contrast, D-Dimer levels were raised at relatively normal activity of antiplasmin (D-Dimer - AP 50-75iu/dL: 
135,161ng/mL; AP 76-100iu/dL: 58,606ng/mL; AP 101-125iu/dL: 24,713ng/mL; *p<0.05 vs AP 150-175iu/dL: 
12,547ng/mL). 
































































































3.3.4 Clinical outcomes 
The small number of patients with severe FA had a high mortality (6/15, 40%), but those 
with moderate FA were a larger group and despite having a lower rate of deaths, had a 
higher number of deaths overall (20/165, 12%).  Patients with moderate FA had a 12-fold 
increase in 28-day mortality compared to patients with no lysis (Figure 3.4, Table 3-2).   PAP 
levels were independently associated with 28-day mortality in a multiple regression 
analysis including age, mechanism of injury, injury severity, admission systolic blood 
pressure and base deficit (r2=0·24; PAP p<0·001). Of the patients who died in the severe FA 
group the average time to death was less than a day and all deaths occurred within 48 
hours. 
There was an association between severity of fibrinolysis and the average number of blood 
transfusions per patient (Figure 3.4B). PAP levels were independently associated with 24-
hour red cell requirements in a multiple regression analysis including mechanism of injury, 
injury severity, admission systolic blood pressure, base deficit and prothrombin ratio 
(r2=0·24; PAP p<0·001).   Patients with moderate FA were also more likely to receive 
plasma (20% vs 2%, p<0·001 - Figure 3.4C), platelet (12.7% vs 0%, p<0·001) and 
cryoprecipitate transfusions (11.5% vs 0%, p<0·001).  Compared with the ‘normal’ group, 
survivors with moderate FA had increased incidence of septic complications (48% vs 3%, 
p<0·001), fewer 28-day ventilator-free days (27 vs 28 days, p<0·028) and spent longer in 
hospital (11 vs 2 days, p<0·001 - Figure 3.4D). The ROTEM only lysis group again reflected a 
relatively uninjured cohort with 0% mortality, no use of blood or products and a median 





    
 
        
Figure 3.4 Outcomes associated with moderate and severe fibrinolysis 
A: Significantly higher mortality in Moderate (12%, p<0.001) and Severe fibrinolysis (40%, 
p<0.05) vs normal (1%). 
B: Moderate and Severe fibrinolysis is associated with higher PRBC transfusion (Moderate 
vs normal and severe vs normal p<0.001 both groups). 
C:  Higher fresh frozen plasma (FFP) requirements in Moderate (1.0 units) and Severe (2.87 
units) fibrinolysis (Moderate vs normal and severe vs normal p<0.001 both groups). 
D: Hospital length of stay in survivors is increased Vs normal (99 survivors, 5.7days) in 
Moderate (145 survivors, 21.5 days), and Severe (9 survivors, 24.1 days) fibrinolytic groups 































































































We have identified that FA, as measured by increased levels of PAP, tPA and D-Dimer, 
occurs in almost two thirds of trauma patients, and the degree of FA is associated with 
increasing injury and with significantly worse transfusion requirements, morbidity and 
mortality.  This high rate of FA has not been identified previously, but it is consistent with 
previous work(30), and the efficacy of tranexamic acid in reducing mortality in bleeding 
trauma patients(34).   
Moreover, more than 90% of FA in trauma patients is not detected by the current 
definition of TEM hyperfibrinolysis. Six in every ten patients presented with moderate FA, 
but only 1 in 20 showed TEM hyperfibrinolysis.   We have shown that increased FA occurs 
without visible clot lysis by thromboelastometry, despite similar levels of D-Dimer 
generation as in those patients with TEM hyperfibrinolysis; and that patients with even 
moderate FA have significantly increased transfusion requirements and other adverse 
outcomes. The observed FA was not a consequence of hypothermia (at least at levels seen 
in our study (20)).  FA is therefore a real pathophysiological entity with important 
consequences for trauma patients. This is of concern in the pragmatic management of 
bleeding trauma patients.  The group with moderate FA are larger and account for more 
deaths than those with TEM hyperfibrinolysis, and would have potentially benefited from 
the use of antifibrinolytics.  
It is unclear under what circumstances TEM detects fibrinolytic activity.  It is possible that 
TEM is simply insensitive until FA reaches a certain threshold.  Free plasmin is rapidly 
hydrolysed and has a very short half-life.  In the TEM cup, free tPA is required to generate 
new plasmin for clot breakdown. This was only seen when tPA levels were nearly 5 times 
normal and alpha-2 antiplasmin levels were significantly reduced to below 75%.  TEM 
hyperfibrinolysis may only occur when there is insufficient antiplasmin to block the action 
of all free plasmin generated in the sample well. Certainly the finding that the addition of 
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aprotinin, a stoichiometric inhibitor of plasmin, to the TEM cups improved the TEM ML 
trace of those with TEM hyperfibrinolysis, but did not alter the traces of others with FA, 
suggests that generation of free plasmin is necessary to produce the TEM hyperfibrinolysis.  
Further research is required to examine this and identify methods to increase the 
sensitivity of TEM. 
There are a number of limitations to our study. Although we have identified that trauma 
patients have increased FA and that the degree of activation is associated with increased 
transfusion requirements and worse outcomes, we have not shown that these levels are 
associated with an increase in clot breakdown or fragility.  We used D-Dimer levels to 
measure the overall results of fibrinolysis, but D-Dimer levels are a marker of 
prothrombotic fibrin generation as well as fibrinolytic activity. We witnessed significantly 
higher levels of PF1+2 in the ‘severe’ group and it is not possible to separate the effects of 
these two processes based on D-Dimer levels alone.  The PAP levels probably represent a 
more robust marker of the activity of the fibrinolytic system itself. We did not investigate 
the value of the various stimuli that drive the generation of FA and these mechanisms will 
require further basic and clinical research.  Finally, although TAFI did not appear to be a 
major factor in the systemic regulation of fibrinolysis it may have an important role in 
intrinsic clot stability and its role needs further elucidation. 
In summary, we have identified FA in the majority of trauma patients and that the degree 
of FA is associated with significantly worse outcomes in terms of transfusion requirements, 
mortality and morbidity. These findings provide a logical explanation for apparent paradox 
that antifibrinolytic therapy appears to have broad application in trauma and elective 
surgery and yet that massive near-fatal trauma is required to produce detectable changes 
on a TEM. The discovery of FA in two thirds of trauma patients presents new opportunities 
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for the development of diagnostic modalities and targeted therapeutic intervention to 




  Chapter 4
The relative contributions of Plasminogen Activator Inhibitor-1, 
Thrombin Activatable Fibrinolysis Inhibitor and Factor XI in 





The importance of fibrinolysis as a mechanism in ATC is now well established. CRASH-2, a 
large scale pragmatic trial with over 20,000 subjects has shown the benefits of 
antifibrinolytic therapy in trauma(34). At the other end of the scale smaller studies have 
shown the coagulation protein changes that suggest that fibrinolytic activation is 
responsible as a major part of the derangement seen in ATC (Chapter 3 above). Brohi and 
others have also shown previously that fibrinolysis is an important mechanism and alluded 
to some of the proteins involved(25,30). Two main inhibitors of fibrinolysis have been 
described in the literature. PAI-1 and TAFI. Factor XI has also been implicated in the 
stabilisation of clot and curtailing of fibrinolysis(55). The relative contributions of these 
proteins in modulating fibrinolysis is not clear. 
4.1.1 Plasminogen Activator Inhibitor 1 (PAI1) 
PAI-1 is a single chain glycoprotein released by many cell types including endothelial cells, 
monocytes, macrophages, platelets, hepatocytes, as well as adipocytes(56). It is one of the 
main inhibitors of plasminogen activation. Its main action is the inhibition of tissue-type 
plasminogen activator (tPA). This is achieved by binding in complex with tPA and 
preventing it from converting plasminogen to plasmin(57). The role of aPC in 
anticoagulation by inhibiting the factor V and VIII pathways is well known but its 
antifibrinolytic effects, although established for some time(28,58), are less well 
understood. Associations have been drawn to suggest that PAI-1 inhibition by aPC is an 
important mechanism in trauma(30). But other groups have demonstrated associations 
suggesting that overwhelming tPA release is the main driver for fibrinolysis with little effect 




4.1.2 Thrombin Activatable Fibrinolysis Inhibitor (TAFI) 
TAFI (also known as procarboxypeptidase B) is a glycoprotein that is synthesised in the 
liver. It is activated by thrombin but it has been shown that thrombin-thrombomodulin 
complex speeds up TAFI conversion to activated TAFI (TAFIa)(60) by up to 1250 fold. TAFIa 
acts as an inhibitor of fibrinolysis by binding to fibrin and cleaving it’s lysine and arginine 
residues. This reduces its co-factor function in plasminogen activation and also makes fibrin 
more resistant to cleavage by the tPA-plasmin complex(61,62). Control of this mechanism 
could indeed be a modulating factor in control of fibrinolysis. Indeed animal studies have 
shown that inhibition of TAFIa by potato carboxypeptidase inhibitor (PCI) does promote 
fibrinolysis in vivo(63–65). In contrast, from human observational data in trauma, it has 
been postulated that the role of TAFIa is not clinically relevant(30). This relationship needs 
further examination. 
4.1.3 Factor XI (FXI) 
The role of factor XI in modulation or indeed control of fibrinolysis is not immediately clear. 
Historically it had been labelled in the intrinsic pathway of coagulation. In the current 
understanding of the cell based model(66) it forms part of the amplification and 
propagation phase of coagulation and seems to have no direct input into fibrinolysis. 
However, observations in subjects with FXI deficiency have noted that bleeding, when it 
occurs, does so from sites of tissue with enhanced fibrinolytic activity(67,68). Furthermore, 
in vitro studies have demonstrated that inhibition of FXI promotes fibrinolysis(55,69). Von 
Dem Borne and colleagues have shown that in a system of activation by tissue factor (tF) 
where lysis was initiated by tPA, the addition of FXIa (activated FXI) inhibiting antibody 
improved lysis almost two-fold compared to addition of buffer(55)(fig 4.1). This suggests 
that the presence of FXI attenuates fibrinolysis and its neutralisation promotes lysis. An in 
vivo rabbit model has demonstrated a similar findings(64). Importantly in this study, 
blocking TAFI or FXI had similar effects. Moreover there was no additional effect from 
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blocking both simultaneously leading the authors to postulate that the effects of FXI on 
sustaining clot are mediated indirectly via the TAFI pathway. 
Our aim with this work, therefore, is to understand the relative contributions of PAI-1, TAFI 
and FXI on curtailing fibrinolysis in humans in a trauma setting. 
4.2 Methods 
4.2.1 Study Design 
This was an observational cohort study nested in the ACIT2 trial already described above. 
The patient group was the same as that in chapter 3 as were the recruitment and blood 
sampling processes. Data collected for the above study was used in this study but analysed 
in a different way as detailed below. 
4.2.2 Blood sampling 
Blood sampling had already been carried out as for ACIT2 above. Specifically for this aim we 
were interested in tPA, PAP, PAI-1, TAFI, TAFIa, FXI and D-Dimer. These tests were used to 
investigate the fibrinolytic pathway in more detail. 
4.2.3 Data processing 
Once data had been collected and all blood results collated special subsets of the data were 
created. Since we needed to understand the effect of the 3 above coagulation factors on 
fibrinolysis specifically the data was split in such a way as to identify those patients in 
 
Figure 4.1 Presence of FXI attenuates clot lysis. 
Clot lysis time with differing concentrations of tPA to initiate lysis. Open bar with added buffer, 





whom there was a significant potential for fibrinolytic activation. Thus the patient cohort 
was initially split into quartiles of tPA.  The highest quartile was taken as the group of 
interest as clearly these patients would have the greatest fibrinolytic potential. Within this 
group quartiles of PAI-1, FXI, TAFI and TAFIa were created. The levels of PAI-1 and PAP 
were compared in this group. FXI activity was also compared to PAP. As TAFIa does not act 
on the Plasmin, TAFI was instead analysed in the context of D-Dimer; a downstream 
measure of fibrinolysis. TAFIa was also examined compared to D-Dimer in the lowest 
quartile of tPA to understand if they had any effect on fibrinolysis where there was minimal 
and not overwhelming fibrinolytic potential. 
4.2.4 Statistical analysis 
All the data processing and statistical testing was carried out in MATLAB (Mathworks, 
Natick, MA, USA). The Kruskal-Wallis test was used to compare the groups where more 
than two group comparisons were required. No assumption was made about the 
distribution of the variables (parametric or otherwise). A p value of <0·05 was chosen to 





303 patients were recruited in total for this study as part of ACIT2. 296 patients had tPA 
measured. Therefore when they were split into quartiles 74 patients remained in each 
quartile. Summary data for the quartiles of tPA is shown in table 4.1. The normal range for 
the Asserachrom tPA ELISA in humans is 2-12 ng/ml. The highest quartile of tPA had a range 
of values for tPA from 13-167 ng/ml. As tPA levels rose PAP levels rose also, and as PAP 
levels rose D-Dimer also increased (fig 4.2A and B). This demonstrates that where there 
was high fibrinolytic potential (as evidenced by tPA) fibrinolysis was indeed occurring (as 
evidenced by PAP and D-Dimer).    
Table 4-1 Quartiles of tPA - ISS; Injury severity score, INR; international normalised ratio, 
ROTEM CA5; mean clot amplitude at 5 minutes on ROTEM, ROTEM MCF; mean maximum 
clot firmness on ROTEM, 24 hour PRBCs; mean RBC transfusion in first 24 hours, 24 hour 
FFP; mean FFP transfusion in first 24 hours. 
 Quartile 1 Quartile 2 Quartile 3 Quartile 4 
Base Deficit (mmol/l) 0.26 0.88 3.08 4.82 
ISS 10 14 15 22 
% Penetrating trauma 27% 20% 26% 11% 
Age 30 37 39 42 
% Male 78.3 85.1 86.5 78.4 
INR 1.1 1.1 1.3 1.2 
ROTEM CA5 (mm) 43 43 42 41 
ROTEM MCF (mm) 59 59 59 57 
24 hour PRBCs (units) 0.14 0.30 1.57 4.11 
24 hour FFP (units) 0.08 0.12 0.72 2.04 
Ventilator free days 27.2 26.9 26.8 26.2 





A B  
Figure 4.2 tPA and D-Dimer 
A)Relationship between tPA and PAP 
B) Relationship between PAP and D-Dimer 
Points plotted are mean and error bars are standard error of the mean. 





































The normal quoted range given for the Asserachrom PAI-1 ELISA was 4-43 ng/ml. PAI-1 was 
also split into quartiles to understand its relationship better. When PAP was compared to 
quartiles of PAI-1; PAP levels were low in the lowest quartile of PAI-1 and rose as PAI-1 
levels went up but in the highest quartile of PAI-1; PAP was low again (fig 4.3A). This 
relationship is not easy to explain.  We then looked at this relationship only in the highest 
quartile of tPA (where there was significant fibrinolytic potential). In this group overall PAP 
levels were higher as would be expected when tPA was high. In the highest quartile of PAI-
1 PAP was significantly lower compared to other PAI-1 quartiles, suggesting that high PAI-1 
levels may have an inhibitory role on Plasminogen activation (fig 4.3B).  
 
  
A B  
Figure 4.3 PAI-1 and PAP 
A) Quartiles of PAI-1 in all patients 
B) Quartiles of PAI-1 in highest quartile of tPA. *- significantly lower than other quartiles, 
p<0.05 
Points plotted are mean and error bars are standard error of the mean. 
 


































The normal quoted range given for the Asserachrom TAFIa ELISA is 8.53 to 22.07 ng/mL. 
When TAFIa was compared to D-Dimer in the highest tPA quartile the relationship seemed 
to correlate very well (fig 4.4A). This is counterintuitive as there should be a negative 
correlation if measured circulating TAFIa was truly inhibitory to fibrinolysis. We went on to 
examine the relationship in the lowest quartile of tPA to understand if TAFIa could inhibit 
fibrinolysis where there was much lower pressure for fibrinolysis to occur. In this group also 
the relationship was similar (fig 4.4B) suggesting that the TAFIa pathway is not a major 




A B  
Figure 4.4 TAFIa and tPA 
A) Quartiles of TAFI1 in highest quartile of tPA 
B) Quartiles of TAFI1 in lowest quartile of tPA 
*- significantly higher than other quartiles, p<0.05 
Points plotted are mean and error bars are standard error of the mean. 
 











































4.3.3 FXI  
The quoted normal range for FXI activity is 48-158 iu/dL. In the highest quartile of tPA there 
is an inverse relationship between FXI activity and PAP levels. Where FXI activity was 
maintained PAP levels were higher than normal but in the lowest quartile of FXI; PAP levels 
were significantly higher (fig 4.5A). FXI activity in this quartile ranged from 11 to 84iu/dL 
with a median activity of 69iu/dL. Indeed this activity is very low. Since the specific 
mechanism for influence of FXI on fibrinolysis is not known, FXI was also compared with D-
Dimer (fig 4.5B). The relationship with D-Dimer may be an important one as there is some 
suggestion that FXI influences fibrinolysis via the TAFI pathway(55).  
 
  
A   B  
Figure 4.5 Factor XI and lysis 
A) PAP levels at different quartiles of FXI in the highest tPA quartile *- significantly higher than 
other quartiles, p<0.05 
B) D-Dimer levels at different quartiles of FXI in the highest tPA quartile 
Points plotted are mean and error bars are standard error of the mean. 
 








































The specific mechanisms in acute traumatic coagulopathy and the dominant coagulation 
system pathways need to be established with further clarity. This will help us to understand 
the processes involved but more importantly tailor interventions and management 
accordingly. This work is aimed at understanding some of these pathways. 
We have shown that PAI-1 levels where high are associated with lower levels of PAP and 
therefore fibrinolysis, even in the cohort of patients where there is raised tPA and 
therefore a significant drive towards fibrinolysis.  PAI-1 may therefore be an important 
control mechanism in fibrinolysis in trauma. The Denver group have suggested that 
fibrinolytic activation is dependant more on overwhelming tPA release binding free PAI-1 
than on PAI1 depletion by aPC(59). Their assertion is therefore that research focus should 
be kept more on tPA upregulation than on PAI-1. But our work shows that even in the 
presence of high tPA levels, Increased PAI1 is associated with lower levels of FA, suggesting 
that PAI1 still has a modulating effect and is not simply overwhelmed. Whether it is 
depleted by tPA or inhibited by aPC it could still be a target for intervention and control.  
The role of circulating TAFI is not immediately obvious in trauma. Animal studies have 
shown that circulating TAFI can have an inhibitory effect on fibrinolysis in vivo(63–65). But 
our observations demonstrate no such response. TAFIa is simply correlated well with rise in 
D-Dimer, suggesting that rises in TAFIa levels are associated with higher levels of 
fibrinolysis; contrary to its expected role. The clinical relevance of measuring circulating 
TAFI or TAFIa have been brought into question previously in trauma also(30). In our 
observations, TAFIa seems to simply be a marker of fibrinolysis rather than a controlling 
factor. Why this should be is an interesting question. Perhaps the expected mechanism of 
action may explain this somewhat. TAFIa binds to formed partially degraded fibrin. This 
binding then curtails further degradation by plasmin and therefore fibrinolysis (fig 4.6) in a 
competitive manner. But the formation of fibrin is the final step in a mechanism that may 
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simply overwhelm the mechanism by which TAFI works. In massive blunt trauma where 
clot formation may not be localised to a single locus, this may be particularly so. 
It has also been shown that as well as circulating in blood TAFI is also present in 
platelets(70). This could potentially be an important source of TAFI and may well be the 
dominant source of fibrinolytic inhibition on a very local level. Of course this would be 
incredibly difficult to measure or investigate and therefore, at present, understanding the 
role of TAFI remains challenging.       
Plasmin can also activate TAFI (71)by cleaving it to form activated TAFI (TAFIa), but this 
mechanism is more difficult to understand as it seems that plasmin also inactivates TAFIa 
and this might well be a modulating mechanism for Plasmin to promote fibrinolysis. In our 
cohort of trauma patients we have already shown that PAP levels and fibrinolytic activation 
is much higher than previously described (chapter 3). This activation of Plasmin may well be 
responsible for cleaving and inactivating TAFIa and thus negating its role as an important 
inhibitor in this process. 
 
Figure 4.6 TAFI and PAI-1  




See also plasmin paper by Marx first paragraph(71). Maybe TAFI only blocks the positive 
feedback loop so its effects in trauma are minimal 
Our observations regarding FXI and its relationship with fibrinolysis mirror some of the in 
vitro work closely. In our cohort (in the highest quartile of tPA) FXI activity, where relatively 
well preserved (quartiles 2,3 & 4 of FXI), was associated with moderate levels of PAP. But in 
the lowest quartile of FXI the levels of PAP were observed to be very high (between 16,000 
and 20,000 mcg/L – Fig4.5A). FXI activity in this group was much lower than other groups 
(range 11-84iu/dL). This is similar to the in vitro data where clot lysis occurred rapidly when 
FXI was inhibited(55)(Fig4.1).  These data would suggest that depletion of FXI promotes 
fibrinolysis, rather than high levels of FXI attenuating it. The mechanisms for this are not 
clear.    
FXI mediated thrombin generation is an important mechanism of clot propagation(72) once 
initial tissue factor burst has occurred. In-vitro data have shown that this clot propagation 
and FXI dependant thrombin generation is responsible for inhibition of fibrinolysis(73). 
Although there has been suggestion that this mechanism works by promoting thrombin 
generation and TAFI activation(74) our observations above would suggest that this may not 
be the dominant pathway since the concentration of circulating TAFI does not seem to be 
related to inhibition of fibrinolysis. Certainly more evidence (probably in vitro and in vivo) is 
required to elucidate the specific mechanism further. 
Our observations in this study do mirror and support some of the previous in vitro and in 
vivo work. And this work is part of an increasing body of evidence from observational 
cohorts of trauma. Historically, this type of work has been invaluable in beginning to 
understand the mechanisms involved in ATC and TIC and relate them to evidence from lab 
and basic science research. Unfortunately this type of data can only draw conclusions on 
associations and not on causation and molecular mechanisms. We have also not taken into 
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account here the possible contribution of platelets to the whole process. As stated above, 
platelets may be an important or even dominant contributor to the role of TAFI. It may 
certainly play a role in PAI-1 and FXI modulation also. Certainly since the better 
understanding of the cell based model of coagulation the importance of the role of 
platelets has led to much research interest and this will continue. In this work, however, it 
is difficult to include platelets in a meaningful analysis. 
 In addition one of the further challenges (if not main difficulty) in this type of observation 
is the large number of possible variables that may confound findings. For example the FXI 
activity may well be influencing other factors. We do know that there is a pathway to relate 
FXI to fibrinolysis so it is appropriate that we compare these but it is entirely possible that 
these are simple correlations and other confounders need to be addressed. With so many 
factors involved in the coagulation pathway, even when the mechanism is not under stress 
(such as in trauma), it is challenging to fully appreciate the systems involved. In a situation 
such as trauma this becomes even more challenging. 
We need to explore other ways of understanding and analysing this data and one possible 
route is to leverage exploratory data analysis techniques which are becoming more 
ubiquitous when looking at large bodies of data. In the following chapters we will use these 




  Chapter 5





The traditional scientific method is based on making observations, perceiving trends, 
formulating hypotheses, collecting data and then analysing that data against said 
hypotheses. The hypotheses are based on the perceived trends and the observations made 
at the outset. This is an effective method and essentially the backbone of most scientific 
and medical research historically. In the modern world where we have tools to collect, 
store and analyse large amounts of data, this paradigm is being challenged. Part of the 
problem with this type of process is that our own biases are introduced even from an early 
stage. This may not be a bad thing since our observations and perceptions of trends may 
well be quite accurate. The human brain is capable of classifying trends effectively and over 
hundreds of years the scientific method has served us very well indeed. But is there a 
different way? When we formulate a hypothesis, immediately we introduce a bias into the 
way we look at data. Perhaps if we had looked more openly at everything the dataset had 
to offer we may arrive at important conclusions which may not have been otherwise 
obvious. This is where exploratory data analysis can be helpful. It is particularly helpful in 
very large datasets which we are now capable of generating. These large datasets may not 
lend themselves to being easily observed or in fact easily examined by traditional 
techniques. Exploratory data analysis should not be seen as a replacement to the scientific 
method. It can be used as an adjunct and at times a precursor to gain an initial 
understanding of data. 
An advantage of using exploratory data analysis techniques is that they can help to simplify 
or reduce the dimensionality of data. For example, if we take a simple process where a few 
variables are involved in a mechanism and we are unsure which are important and how 
they relate to each other, one way to begin analysing the data may be to plot x against y 
and look at the result. We may even be able to add a third variable to the plot to 
understand how the three relate to each other. Beyond three variables simultaneously, in 
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conventional statistics and data analysis we couldn’t visualise the relationship. Even 
without the need to visualise the relationship it may be difficult to understand it. Multiple 
regression analysis is sometimes used to explore the relationships between many variables. 
Even this is limited to essentially outputting an equation and finding best fit parameters. 
And in reality, multiple regression still only analyses the relationship between lots of 
variables and how each relates to only one output variable. In order to understand and 
explore more variables at the same time we need to utilise more complex techniques. 
Techniques which look at very large numbers of variables and aim to reduce them are 
known as dimension reduction techniques. Principal component analysis is an example of 
dimension reduction. Techniques which look at very large numbers of observations (which 
may also have many variables) and look to reduce these or group them are broadly known 
as classification or clustering techniques. Both these types of analysis are used to explore 
large datasets and can be set up to do so in an unbiased manner. 
5.1.1 Clustering 
Clustering is a technique in which observations are classified into groups based on their 
similarity to other observations. Similarity measures are calculated across all variables 
simultaneously in order to classify any given observation. This is the main power of the 
technique. Various types of clustering techniques exist and even within each type further 
subcategories and specialisations have been produced over time to work with specific 
types of data sets. The most common use of clustering in the medical sciences is to classify 
gene expression data. This can be done at both DNA and RNA levels. Increasingly this type 
of analysis is being used to understand cancer biology and to tailor interventions 
appropriately. Examples in breast(75,76) and lung tumours(77) exist but the technique is 
being more widely used to good effect. 
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Types of clustering 
As stated previously multiple clustering methods have been defined. The main types and 
those in commonest use include hierarchical clustering, K-means clustering and density 
based clustering. They each have their advantages and disadvantages but these may be 
specific to types of dataset. 
5.1.2 Hierarchical clustering 
This is perhaps the most straightforward type. It is an example of unsupervised learning. 
That is, it requires no specific starting conditions and once set up and will cluster without 
further input from the user. In this respect it minimises bias as much as possible. It results 
in good visualisations of output and therefore is helpful in giving a good overview of the 
data visually so giving us a better understanding(78). It is a relatively simple technique and 
therefore easily accessible. Most bioinformatics programmes will be able to handle this 
type of clustering. Its disadvantage is as a result of its simplicity. Because complex 
calculations are not being carried out, a lot of calculations are required and therefore it is 
very computationally expensive and inefficient.    
5.1.3 K-means clustering 
This type of clustering works in a very similar way but requires the user to set the number 
of clusters or the ‘k’ prior to starting. It also needs further inputs to begin clustering and so 
introduces a potential for bias. Having said this, many strategies and mechanisms exist to 
minimise this bias of human input. K-means is a more complicated method overall than 
hierarchical and therefore is less accessible to those not proficient in these methods. 
Importantly it is also a stochastic method, that is to say it is much more statistically based 
and even inputting the same ‘seed’ data may reveal subtly differing outcomes. In very large 
datasets this may not be an issue but in smaller datasets (like ours) this certainly would give 
one less confidence. Compare this to hierarchical clustering which is deterministic. This 
means that if the same process is run then the same outputs from the algorithm will result. 
This makes results reproducible in smaller datasets which may be a requirement. Many 
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different variations of K-means clustering exist and are in common use for various different 
applications(79). 
5.1.4 Density based clustering 
This type of clustering has the advantage of being computationally very efficient. This lends 
itself much more to use in very large datasets. It also has the benefit of dealing much better 
with outliers than the other methods. However, many more inputs are required to run the 
algorithm and much more specialist knowledge and indeed software is required. It is also 
not as easy to interpret the outputs visually. All this means that it is not as easily accessible 
to less experienced data handlers who are working on smaller datasets. Indeed, one could 
argue that if datasets are not very large this type of clustering holds minimal advantages.  
For the purposes of our analysis hierarchical clustering is more than adequate and has the 
advantage of being easy to access and reproducible across smaller datasets with good 




5.2 Methods to prepare data for clustering 
5.2.1 Patient recruitment and data acquisition 
The patients for this part of the study were recruited in the same manner as those 
described above. As well as the first 323 original ACIT2 patients, recruitment continued and 
eventually included the patients and samples recruited by our European partners. In all, the 
data that is presented here comprises patients recruited from January 2008 until July 2014. 
It should be noted that study recruitment continues to the present time. All patients were 
recruited and consent obtained according to the same criteria detailed above, with local 
variation based on each centre’s own ethical approval. The timescale for blood sample 
collection and processing was the same everywhere irrespective of local centre variation in 
other administrative aspects. Once the samples had been processed and stored (in line 
with the SOP detailed in chapter 2, section 2.4/fig2.1), they were eventually returned to 
our centre and sample analysis undertaken when funds and sample kits were made 
available. All centres also collected the same patient data as detailed above in section 2.7. 
This included data on patient demographics, injury characteristics, IV fluids and blood 
transfusion in the first 24 hours and outcome data. 
All of the above data acquisition resulted in a large data set comprising various types of 
data. For ease of description later on I have split these into discrete data sections; 
Demographic and injury (D&I) data 
All the data obtained at admission describing the patient demographics, injury 
characteristics, (AIS and) ISS data worked out by our TARN (trauma audit and research 
network) data collectors. I have also included initial lab or bedside tests under this category 
such as blood gasses (lactate/base deficit) and admission full blood count etc. This also 




All blood samples collected and analysed by ourselves resulting in ELISAs and all blood 
samples handled by our laboratory to give numbered coagulation factors and a few other 
coagulation proteins as described in detail in chapter 2 and summarised in tables 2-3 and 2-
4. It should be noted here that the decision was made to not proceed further with testing 
of TAFI and TAFIa (ELISAs). This decision was based on various factors. Primarily as a result 
of our work described in chapter 3 and 4 and also undertaken previously(30). Given that 
there was a lack of signal from the circulating TAFI and TAFIa measured in these studies, 
and, the significant cost both in terms of time and money to analyse, what would have 
been, around 2,000 samples (as a minimum), further analysis of these ELISAs was not 
undertaken.  
ROTEM data 
ROTEM data was analysed across all sites based on the SOP previously described and in line 
with the company’s own guidelines. 
Resuscitation fluids (RF) data 
This was detailed data collected on volumes and types of intravenous fluid required in the 
first 24 hours of admission after the initial blood draw. This did not include the fluids given 
that are already accounted for in the D&I data described above. 
Outcome data 
All data collected on outcomes such as 28 day outcome (discharge or death), total LOS, 
critical care days, ventilator free days, vasopressor days and renal replacement therapy 
(RRT) days. 
5.2.3 Data to be imported for clustering 
The aim for this project was to use clustering to understand the coagulation system 
derangements in trauma. The most important dataset in this respect is the biological 
dataset. We wanted to define the different derangements based only on the biological data 
for a number of reasons; 
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 The biological dataset contains all the coagulation protein data. This is essential to 
our understanding of coagulation and coagulopathy. 
 The biological dataset comprised continuous variables which are much more suited 
to analysis by clustering. The other datasets comprise largely discrete and 
categorical data. Some of these are even binary data. Although it is possible to 
cluster these data it is not ideal and much more complex as a method. 
 The other datasets are likely to have more missing data. This is an inherent 
problem in collecting clinical data and can be a difficult problem to deal with.   
5.2.4 Data cleaning 
The process for importing a clean dataset into the clustering algorithm needed to be 
rigorous. I have detailed below the stepwise data process undertaken to achieve this. 
5.2.5 Dealing with missing data 
In order to successfully import a dataset into a clustering algorithm one must have a 
complete dataset. In our dataset missing values occurred mainly where there had been 
either a problem with test itself or where there was insufficient sample to process every 
test. Where blanks in data set occur a few options are open to us in order to proceed(80). 
Deleting the whole sample from that subject is a possibility. The other option is to replace 
the missing value with a calculated value in some way. There are various methods of 
calculation from as simple as using the mean for that particular dataset to much more 
complicated equations to replace values(81). These methods are all broadly known as 
imputation. Statistical model based methods are also used, for example using Bayesian 
network prediction to replace the data. Although the more sophisticated methods are 
certainly better than simple imputation (using means for example), nevertheless they all 
have the potential to introduce bias into the data and thereby reduce the accuracy of 
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analysis and therefore conclusions derived. For this reason the missing data in our dataset 
was dealt with by deleting the subject and using complete-case analysis method only. 
5.2.6 Sorting upper and lower limit values 
There were other instances where data was not missing but was given as a high or low 
level. This occurred with our ELISA data. Where a sample result returned as ‘greater than’ 
the highest interpolatable value given by the manufacturer of the ELISA kit, we attempted 
to redo the test with a half dilution sample to get an accurate reading. If it was still above 
the upper range this was noted. Where a sample appeared to be below the range we were 
unable to dilute or concentrate this further and so this was simply noted in our overall 
database. When coming across these values in the cleaning stages they were replaced with 
the highest or lowest value attributable for that test batch. Although these may not be 
accurate estimates this practice assumes the value is either very high or low, which is 
biologically true and therefore does not unduly bias the result of analysis or interpretation. 
5.2.7 Dealing with outliers 
On the whole outliers were not an issue in the biological dataset. Many time values that 
seemed like outliers were simply very high or low values. All raw data was plotted to 
visualise the possibility of outliers, and for all samples (except one), no deletions were 
required. The one exception to this was a result for Factor VII. The normal range for this 
test was given as up to 50-150 iu/dL. One value returned a result of 7045 iu/dL. The next 
highest value in any FVII assay was 1245 iu/dL. As there was enough sample remaining the 
test was repeated but revealed a similar result. After consultation with our lab manager, 
who supervised this analysis on the Sysmex lab machine, we could not arrive at a 
reasonable conclusion as to why this could be, particularly since the remaining factor and 
ELISA values for the same subject were not outliers. Initially in preliminary clustering this 
subject was left in the analysis since the sample had been repeated and the same value 
returned. But on reflection leaving in such a high value was unduly transforming the 
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remaining FVII values in our data process and therefore destroying the variability seen in 
the FVII dataset.  It was therefore removed before the final analysis.   
5.2.8 Thrombomodulin ELISA 
As described in chapter 2 (section 2.6) our sample processing was run in two batches; upto 
patient 324 in the first batch and then all remaining samples in subsequent batches. All 
tests were reproducible between batches with the exception of the thrombomodulin ELISA. 
This was no longer available by the second batch and therefore a different kit was sought. 
The characteristics for the new kit were quite different (table 2-4). It would have been 
impossible to retrospectively repeat the first batch of samples on the newer kit. At the 
same time excluding one or the other would significantly reduce our sample size and 
available data. Therefore both batches have been left in. It will not be possible to draw 
inferences about the raw values, however, given the normalising process (see below) even 
having different ranges of the nature seen in these two ELISAs does not exclude the whole 
TM dataset from the clustering algorithm.  
5.2.9 Normalising data 
The hierarchical algorithm used will cluster data based on similarity between different tests 
and also between different subjects based on similarity. For the similarity to be accurately 
measured the units of each data point must be similar. Before importing the data into the 
algorithm it must, therefore, be normalised. This ensures that the only thing affecting the 
clustering is the pure variability within the dataset and not units within or between 
datasets. There are various methods of normalising data. They are broadly similar and give 
similar results(82). However, we did note Milligan and Cooper’s observation that using the 
z-score (a commonly used method in some clustering algorithms) can sometimes remove 







Where 𝑹 = the mean of the normal range given by the manufacturer of that test   
Where 𝑿 = the range of values in a given dataset (ie max-min) 
Where 𝒙 = the observed value to be normalised 
 
This transformation was carried out separately within each sample for the batches before 
and after sample 325. Dividing by the range meant that all datasets had a range of 1 and 
were centred around 𝑅. When the two batches were then combined the values were now 





5.3 Methods in Clustering 
Hierarchical clustering works in 3 stages 
1. It seeks to quantify the similarity between observations by measuring the 
mathematical distance between observations. 
2. It uses a linkage algorithm to determine which observations are similar based on 
the mathematical similarity between them 
3. Visualisation and ‘cutting’ of the clustergram and dendrogram to reveal the final 
clusters 
5.3.1 Distance metrics or proximity measures 
In order to achieve the first stage we need to have some way of calculating the difference 
between observations and this is known as the distance metric or the proximity measure. 
To calculate a distance between two observations in two or even three dimensions is 
straightforward. Each dimension here is a variable. In order to calculate the distance in 
more than three dimensions requires more complex mathematical solutions. A number of 
proximity measures exist in order to calculate these distances. These measures are split 
into quantitative or qualitative. Examples of quantitative are Minkowski, Euclidean, 
Manhattan block, Chebychev and squared Mahalanobis distance. Qualitative include 
Pearson correlation and Spellman rank correlation. It is widely accepted that the default 
proximity measure is Euclidean distance(83), and for most applications it performs very 
well. 
5.3.2 Agglomerative or divisive clustering  
To achieve the second stage of discerning similarity (or difference) the clustering method 
can use a number of possible algorithms. These are known as ‘linkage algorithms’. Once the 
distance metrics have been calculated between each observation, the clustering algorithm 
will then apply the linkage algorithm of choice to create the cluster. This can be done in 
two possible ways; agglomerative or divisive. 
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Agglomerative hierarchical clustering is a ‘down to up process’ or sometimes referred 
to as ‘leaves to trunk’. If we assume the number of observations in a complete cohort is n. 
This type of clustering stars with n clusters and combines a cluster with its nearest 
neighbour using the linkage algorithm to guide it. It then keeps joining clusters to other 
clusters until the number of clusters = 1, i.e. all observations are joined into a single cluster. 
Divisive clustering is the opposite. It is a trunk to leaves process where the algorithm 
starts with one cluster that contains all n of the observations. It gradually separates the 1 
into more than one and subsequently many cluster, again based on the linkage algorithm. 
This is continued until there are n clusters. Divisive clustering is much more complex and 
computationally expensive and therefore was rarely ever used. In fact the software suite I 
have used in this project defaults to agglomerative clustering and does not have a built in 
function for divisive clustering. 
5.3.4 The dendrogram 
Hierarchical clustering algorithms output two main constructs; the clustergram (sometimes 
referred to as the heat map) and the dendrogram. The heat map is a graphical 
representation of the whole dataset with colours for each variable in each subject to 
represent whether the observation is high or low compared to a given central point. This in 
itself is an advantageous data analysis adjunct. The true output, however, is the 
dendrogram. This shows the hierarchy of all the clusters and how they relate to each other. 
It shows how many clusters are formed and how the separate (or join) and at what level. 
‘Cutting’ this dendrogram at different levels will reveal different numbers of clusters in the 
dataset ( Example dendrogram Fig 5.1). This is again somewhat of an iterative process 







This does have the potential to introduce bias but coupling this step with the linkage 
method is crucial. Some linkage methods will reveal a very well set out dendrogram where 
clusters are easy to discern and another may reveal a very tightly packed dendrogram 
which separates all levels very closely and so makes it difficult to discern the separation of 
clusters effectively.  
5.3.3 Linkage algorithm 
This linkage algorithm itself is the specific algorithm used to decide on each cluster. Let us 
take the simplest example. Single linkage clustering creates clusters by joining clusters to 
nearest neighbours. This is calculated by finding the nearest 2 points in any given clusters 





Figure 5.1 Example dendrogram 
Cutting this dendrogram at point A will result in 3 clusters whereas cutting at B will 







A number of other linkage methods exist. Two others are also shown in fig 5.1. As all 
datasets are different finding the correct linkage methods is somewhat of a trial and error 
process. This is an exploratory data analysis after all. However, it is acknowledged that 
single linkage method performs poorly in almost all situations(83). As it was one of the 
earliest described methods(84) it is usually included for completeness in almost every 
software package. In this work centroid, average, median, ward and complete linkage 
methods were evaluated in our dataset. Prior to acquiring the international dataset, 
preliminary clustering was run on the same dataset described in chapters 3 and 4. This 
work was presented as an abstract at the European shock society conference in 2013(85). 
Working examples from that preliminary project are shown in Fig 5.3 below. Again single 
linkage was carried out for completeness but its disadvantage is obvious here looking at the 
dendrogram. Centroid, average and median linkages also show a challenging dendrogram 
to interpret and separate and any given level usefully. The two most useful methods for 
this particular dataset were ward and complete linkage. They output dendrograms which 
appear to be well separated and relatively easy to cut to give useful clusters. 
A      B      C 
 
Figure 5.2 Linkage methods 
A) Single linkage – nearest neighbour in another cluster 
B) Centroid linkage – distance between centroids of each cluster 
C) Complete linkage – furthest neighbours in each cluster 







Figure 5.3 Linkage algorithm examples 
Examples of clustergrams and associated dendrograms for six linkage methods, all using 
Euclidean distance metrics. Only Wards Linkage and Complete Linkage seem to perform well 




5.4 Data processing and analysis tools 
Microsoft Excel 2010 (Microsoft Inc., Redmond WA, US) and MATLAB (Mathworks, Natick, 
MA, USA) were the two packages used together during the whole process. Data was 
initially available in various different excel files. These needed to be merged to allow 
analysis of the complete dataset. Collating and merging such large volumes of data 
manually often results in transcription errors. The data was therefore imported into 
MATLAB and its powerful merging tools were utilised to construct the whole dataset. This 
was then exported back to Excel where the biological dataset was prepared for clustering 
as described in section 5.2 above. The final normalised dataset was then reimported into 
MATLAB where the clustering could be carried out using the Bioinformatics Toolbox. The 
dendrogram could be reviewed and decision on cutting made at this stage.  The final 
clustering information was then re-merged with the complete dataset in MATLAB. The 
statistics toolbox could now be used to analyse the output from the clustering.      
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  Chapter 6
Using hierarchical clustering methods to classify coagulation system 




6.1 Introduction and aim 
The acute coagulopathy that occurs early after trauma is an important yet difficult 
mechanism to understand. To date work has shown that fibrinolysis and associated 
mechanisms are responsible for this derangement(25,30 & chapter 3 above). A large 
randomised controlled trial of an antifibrinolytic agent showed survival benefit(34). Yet the 
specific derangements are still difficult to fully understand. Moreover, with such a variable 
patient population and such a difference in the possible initial insults there could be more 
than one mechanism at work. This degree of variability in presentation poses challenges in 
understanding and interpretation of trauma data and outcomes. When we do analyse this 
data we may unduly introduce bias into testing and understanding these datasets. As 
datasets get larger we may not be able to understand them at all. A need exists to try and 
understand this degree of variability in an unbiased way. 
Hierarchical clustering may provide a good solution to begin to understand these types of 
data. Clustering has been used ubiquitously in exploration of gene expression data and very 
large data sets. Very few people have attempted to use it on medium sized datasets in the 
medical fraternity on non-genetic data. In theory it would provide a good solution to 
explore a dataset of hundreds of individuals with multiple variables associated with each 
observation. However, since hierarchical clustering has not been used in this context 
before, a bespoke solution may need to be sought to achieve this. 
My next aim therefore is to utilise a hierarchical clustering algorithm on biological 





6.2 Study design 
Trauma patients were recruited to an ongoing multicentre prospective observational 
cohort study. Five discrete datasets were collected from each patient. The recruitment and 
data collection has been described in detail in previous chapters. The data from all 
European centres was collated. The biological dataset was extracted and appropriately 
prepared for cluster analysis. This data was imported into a hierarchical clustering 
algorithm for analysis to classify the different coagulation system derangements. 
6.2.1 Statistical analysis 
All data were analysed in MATLAB (Mathworks, Natick, MA, USA) utilising its statistics 
toolbox. Since there were more than two clusters (groups) to compare, the Kruskall-Wallis 
test was used to compare groups. No assumption was made about the distribution of the 
groups at the time of testing. The ‘multicompare’ tool in matlab was used to understand 
the output of the Kruskall-Wallis test to see which specific groups were statistically 
different to other groups. A p value of 0.05 was chosen as a threshold for significance. Data 
are presented below in the form of mean with 95% confidence intervals, or, if they are 
obviously non-parametric data (such as length of stay), they are presented as median with 
interquartile range. Charting of non-parametric data is done using box and whisker plots 




1539 patients were recruited from a total of 6 European centres between January 2008 and 
July 2014. No less than 118 variables were observed for each patient. This resulted in 
approximately 181,602 data points. Numbers of variables from each dataset were as 
follows;  
 D&I variables 39 
 Biological  21 
 ROTEM  44 
 RF    8 
 Outcomes    6  
The biological dataset was isolated and cleaned in preparation for clustering. 231 patients 
were removed as they had 1 or more blank data fields. 78 further were deleted as they had 
insufficient plasma sample remaining to allow analysis. 1 patient was excluded because of a 
significant outlier. This left us with 1229 patients. In these patients, 149 data points in the 
biological dataset were replaced by high or low values for that variable. The biological 
dataset was separated and imported to the hierarchical clustering algorithm in MATLAB. 
Once the clusters were defined the complete data set was re-merged with the cluster data 
and analysis of clusters could begin. 
6.3.1 Linkage algorithm 
Results were obtained by applying hierarchical clustering to the biological dataset using 
ward and complete linkage algorithms. The dendrogram for complete linkage appeared to 
be relatively well separated but had to be cut at various different levels to obtain a 
reasonable number of clusters. When cut across at the same level it revealed 15 different 
clusters. On the other hand ward linkage performed well, giving a well separated 






























Figure 6.1 – Preceding page and attached separately 
Heat map and dendrogram for biological dataset of 1229 trauma patients. Each column 
represents a patient and each row represents a variable (annotated on the right of the 
heat map; antiplas-α2Antiplasmin, AT-Antithrombin, PC- Protein C, Fib- Fibrinogen, V- 
Factor V, X- Factor X, VII- Factor VII, FreePS- Free Protein S, IX- Factor IX, II- Factor 
II/Prothrombin, XIII- Factor XIII, TM- Thrombomodulin, PAI1- Plasminogen activator 
Inhibitor-1, tPA - Tissue type Plasminogen activator, sFMC- Soluble Fibrin monomer 
complexes, Ddimer- D-Dimer, PT12- Prothrombin fragment 1&2 ,PAP- Plasmin-
Antiplasmin complex ,VII-Factor VII ,VWF:Ag- von Willebrand Antigen). 
6 clusters are seen as depicted by the different colours on the dendrogram.  
Cluster 1 – Dark Blue – 391 patients 
Cluster 2 – Green - 227 patients 
Cluster 3 – Red - 284 patients 
Cluster 4 – Yellow - 145 patients 
Cluster 5 – Light Blue - 148 patients 
Cluster 6 – Magenta - 34 patients 
The colours in each cell represent the value of the normalised variable for that subject. 
The normalised values are opposite to the true values in relation to the mean of the 
sample’s normal range. Therefore, when considering the original raw variable, red cells 
depict low levels compared to the normal range and blue depict high levels, with green 
(‘0’) being the mean of the normal range for that variable.  






6.3.2 Demographics and injury (D&I) dataset  
All the D&I data are summarised in tables 6-1 and 6-2. All six clusters show subtle as well as 
obvious differences in their presenting characteristics. It should be re-iterated here that all 
these clusters were formed in an unbiased manner from the information in the biological 
dataset only. 
Cluster 3 (C3) is the least injured with a median ISS of 9. This might suggest it was the most 
“normal” cluster. Clusters 4, 5 and 6 had severe injuries with ISS of >25 (fig 6.3). In terms of 
specific injury pattern, cluster 5 (C5) showed more polytrauma with injuries in all regions 
but certainly a predominant element is head injuries compared to other clusters. C6 also 
present with polytrauma but without the significant head injury element seen in C5. C4 also 
showed polytrauma but not to the degree of C5 and C6.  
It is interesting to note that by clustering the protein data a group has emerged that is 
older than the other groups (C5). Whether this has been selected by the protein data or 
whether these subjects are more likely to suffer trauma and then result in particular 
patterns of coagulation derangement is an interesting question. This group also have fewer 
males but overall the proportion of males is still high (as expected in the trauma 
population). C5 also has appreciably lower penetrating injuries with almost 100% being 
blunt trauma. 
C4 and 5 also took the longest to arrive at the hospital post injury (C6 also but did not reach 
significance). The difference is not is not more than 10-15 minutes but does likely represent 
the complicated nature of injuries as well as transfer. 
The degree of physiological derangement is also important. C2, although not severely 
injured (as characterised by ISS) were nevertheless shocked overall as a group with high 
lactate and base deficit. But C4, 5 and 6 were significantly more shocked on arrival. C6 
being the most extreme as a group. C6 also received the most fluid resuscitation and blood 
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product before blood draw. The Haematocrit is also lower for C5 and 6 (although still in the 
normal range). This would suggest either dilution of perhaps blood loss in these groups. 
It is also important to note the temperature on arrival in C5 was significantly lower (fig 6.2), 
although still not low enough to be labelled hypothermic or in fact at the level where it 
should affect coagulation(20). 
The degree of platelet reduction is also important to note (Fig 6.4). This may simply be due 
to dilution (Fig 6.4) or some element of “depletion”. Nevertheless it remains above 150,000 
per µL and certainly this is not so low to be considered a frank “consumption” such as 




Table 6-1 Demographics and injury characteristics 
Significance testing between clusters. * denotes significant difference compared to cluster 1, + denotes significant difference compared to cluster 2 and 
‡ denotes significance compared to cluster 3.  Demographics and shown as mean (and confidence intervals). Injury characteristics are shown as median 
(and interquartile range). Significance denotes p<0.05 but in many cases p<0.01 
Clusters 1 2 3 4 5 6 
Age (years) 41.2(40-43) 43.6(41-46) 38.8(37-41)+‡ 39.6(36-43) 48.6(45-52) * 42.5(36-49) 
% Male 84(81-88)+ 72(66-78) * 81(76-85) 79(72-85) 68(60-75) *‡ 62(45-79) * 
% penetrating trauma 19(15-23) 17(12-22) 16(12-21) 14(8-19) 3(0-5) *+‡ 21(6-35) 
% intubated 29(24-33) 33(27-39) 29(23-34) 50(41-58) *+‡ 74(67-81) *+‡ 62(45-79) *+‡ 
Time from Injury to ED 
(mins) 
65(62-69) 63(59-67) 69(65-72) 76(72-81) *+‡ 79(75-84) *+‡ 79(63-95) 
Injury Characteristics 
ISS 13(5-22) ‡ 13(6-25) ‡ 9(4-16) *+ 25(15-30) *+‡ 30(25-41) *+‡ 29(20-40) *+‡ 
AIS Abdomen & Pelvis 0(0-0) 0(0-0) 0(0-0) 0(0-2) *+‡ 0(0-2) *+‡ 2(0-3) *+‡ 
AIS Face 0(0-0) 0(0-0) 0(0-0) 0(0-0) 0(0-1) *+‡ 0(0-0) 
AIS Thorax 0(0-3) ‡ 0(0-3) *‡ 0(0-2) 3(0-4) *+‡ 3(0-4) *+‡ 3(0.5-4) *+‡ 
AIS Head & Neck 0(0-2) 0(0-3) 0(0-2) 0.5(0-4) * 3(0-5) *+‡ 0(0-3.75) 
AIS External 0(0-0) 0(0-1) 0(0-0) 0(0-0) 0(0-0) *+ 0(0-0) 
AIS Extremity & Pelvis 0(0-2) 0(0-3) 0(0-2) 2(0-3) *+‡ 2(0-3) *+‡ 2(0-3.75) ‡ 
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Table 6-2 Admission physiology and early infusions 
Significance testing between clusters. * denotes significant difference compared to cluster 1, + denotes significant difference compared to cluster 2 and 
‡ denotes significance compared to cluster 3.  Demographics and shown as mean (and confidence intervals). Significance denotes p<0.05 but in many 
cases p<0.01 
Clusters 1 2 3 4 5 6 
Admission Physiology 
Glasgow coma score 13(12-13) 12(12-13) 13(12-13) 11(11-12) *+‡ 9(8-10) *+‡ 10(7-13) 
Systolic blood pressure 135(132-137) + 123(119-127) *‡ 138(135-141) + 124(119-129) *‡ 119(113-125) *‡ 100(90-109) *+‡ 
Temperature on arrival 36(35.9-36.1) 36(35.8-36.2) 36(35.9-36.2) 35.8(35.6-36) 35.2(34.7-35.7) *+‡ 35.8(35.2-36.4) 
Lactate 2.9(2.6-3.2) 3.1(2.7-3.6) 2.4(2.1-2.6) 3.5(2.9-4) *+‡ 4.7(4-5.4) *+‡ 6.8(4.8-8.9) *+‡ 
Base deficit -1.5(-1.9--1.2) + -2.9(-3.6--2.2) *‡ -1.1(-1.5--0.7) + -3.4(-4.2--2.6) *‡ -7.6(-8.7--6.4) *+‡ -10.1(-13.5--6.7) *+‡ 
Haematocrit 0.41(0.41-0.42) + 0.39(0.38-0.4) *‡ 0.41(0.4-0.42) + 0.4(0.39-0.41) * 0.37(0.36-0.38) *‡ 0.33(0.25-0.42) *‡ 
Platelet count 238(231-244) + 220(212-228) *‡ 243(235-250) + 232(222-242) 194(183-206) *+‡ 180(154-206) *‡ 
Infusions prior to blood draw 
Crystalloid (mls) 190(154-227) + 316(250-383) *‡ 164(127-201) + 281(215-347) *‡ 423(325-520) *‡ 982(644-1320) *‡ 
Colloid (mls) 0(0-0) 4(-1.6-9.6) 0(0-0) 0(0-0) 12.2(-5-29.5) 17.2(-18.1-52.6) 
Hypertonic saline (mls) 12.3(5.7-18.9) 16.3(5.1-27.6) 5.8(0.6-11.1) 10.1(0.2-19.9) 72(48.8-95.2) *+‡ 60.3(5.5-115.2) *‡ 









Figure 6.2 Admission demographics 
All points are mean and confidence intervals. Significance data is given in the corresponding data 
tables 
 










































































































Figure 6.3 Injury Characteristics 
Box plots are median and interquartile range for each box and whiskers are 2 standard 














































Figure 6.4 Admission Physiology 
All points are mean and confidence intervals. Significance data is given in the corresponding 
data tables 
 




































































All the Biological data are summarised in tables 6-3 and 6-4. Significant and interesting 
derangements are seen in this dataset. This data should also be reviewed with the heat 
map to hand (figure 6.1) as these patterns can be seen visually on the heat map also. 
C1 and C3 appear to have the fewest coagulation derangements. They both have normal 
INR and fibrinogen levels are maintained. The numbered coagulation factor levels are also 
normal in both albeit with C1 having slightly lower levels. What is interesting to note 
however is that C3 has 25% higher PAI-1 than C1. This seems to translate to a lower level of 
fibrinolytic activation (FA) as evidenced by lower PAP. The PAP is not in the normal range in 
any group but the lowest is in C3. D-dimers are also lower suggesting less activation and 
subsequent fibrinolysis.  
Looking at groups C2 and C4 we can appreciate a coagulopathy with both arriving in 
hospital with an INR >1.2 (figure 6.5). C2 in particular is interesting in that these patients 
seem to have a low injury load (figure 6.3), low levels of shock as evidence by low lactate 
and base deficit. Nevertheless they still appear coagulopathic. Certainly they show signs of 
moderate FA with PAP around 3900 mcg/L (figure 6.5) and raised D-dimers. There is a 
significant reduction in α2-antiplasmin which also suggests significant FA. C4 has similar 
characteristics but the injury load and level of shock is higher. The coagulopathy here is 
easier to understand. There are system derangements in keeping with FA of a quite 
significant level with PAP near 10,000 (figure 6.5), relatively high tPA, significant activation 
of coagulation as evidenced by raised thrombin production and utilisation of fibrinogen 
(figure 6.5). There is relative preservation of the numbered coagulation factors (figure 6.6). 
Overall this cluster shows a fibrinolytic phenotype also. 
C5 is a group that demonstrates frank coagulopathy and significant derangements. All are 
in keeping with fibrinolytic activation as C4 but significantly more pronounced. This cluster 
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is perhaps the furthest along the continuum of fibrinolysis than the other groups with a 
mean PAP of 19,500 mcg/L and significant coagulopathy by INR of 1.8. This group is also 
coagulopathic by APTT suggesting a problem with the factors involved in the traditional 
intrinsic pathway. In fact if we examine these factors they are becoming globally reduced. 
Almost all are at their lower limits of normal but are significantly reduced in comparison to 
C1 and C3 and many also compared to C2. 
This trend is taken to the extreme with C6. This is a small group (34 patients) and is 
characterised by the most severe of coagulopathy in comparison to the other groups with 
an INR of 3.0 and an APTT ratio of 2.2. The main coagulation system derangement is the 
global reduction in numbered clotting factors. In some cases as low as 30-40% of normal. In 
fact FV in this group has 20% of normal activity. The most interesting aspect is that this 
group is not characterised by severe fibrinolytic activation like C5. There is FA here but PAP 
and D-dimer levels are around a half of group C5. In addition there seems to be reduced 
thrombin generation as evidenced by reduced PT1+2. C6 also has the highest fibrinogen 
utilisation with a mean fibrinogen of only 0.97 g/dL (figure 6.5). Another important finding 
here is that soluble fibrin monomer complexes (sFMC) are being produced.  Infact the level 
is higher than any other group. This suggests the coagulopathy may be consumptive. 
Platelets in this group were also significantly reduced in comparison to other groups but 
were not low enough to meet criteria for DIC. In fact they were still within what would be a 






Table 6-3 Coagulation factors 1 
Significance testing between clusters. * denotes significant difference compared to cluster 1, + denotes significant difference compared to cluster 2 and 
‡ denotes significance compared to cluster 3.  Protein data is shown as mean (and confidence intervals). Significance denotes p<0.05 but in many cases 
p<0.01 
Clusters 1 2 3 4 5 6 
PAI-1 31.1(28.4-33.7)‡ 26.9(23.3-30.5) ‡ 41.6(35.1-48.1) *+ 39.6(33.1-46.0) + 35.5(30.9-40.2) 25.4(14.8-36.0) 





tPA 15.2(14.3-16.0) ‡ 13.6(12.4-14.7) 11.5(10.5-12.5) * 19.1(17.1-21.0) *+‡ 26.3(22.5-30.1) *+‡ 22.6(16.0-29.1) *+‡ 













Fibrinogen 2.37(2.30-2.44) + 2.02(1.94-2.11) *+‡ 2.36(2.29-2.43) 1.72(1.63-1.82) *+‡ 1.22(1.12-1.31) *+‡ 0.97(0.76-1.19) *+‡ 
sFMC 89(80-97) 98(85-111) 72(63-81) 229(203-255) *+‡ 249(234-265) *+‡ 353(170-537) *+‡ 
α2-
Antiplasmin 
99(98-101) +‡ 76(73-79) *‡ 122(119-125) *+ 88(84-92) *+‡ 45(41-48) *+‡ 31(24-39) *+‡ 
Prothrombin 
time 
11.5(11.4-11.7) 13.8(11.8-15.9) 11.0(11.0-11.2) 14.4(11.2-17.6) 19.5(15.1-24.0) *+‡ 32.6(16.2-49.0) *+‡ 
INR 1.1(1.1-1.1) 1.3(1.1-1.5) 1.1(1.0-1.1) 1.4(1.1-1.6) 1.8(1.4-2.2) *+‡ 3.0(1.6-4.5) *+‡ 





Table 6-4 Coagulation factors 2 
Significance testing between clusters. * denotes significant difference compared to cluster 1, + denotes significant difference compared to cluster 2 and 
‡ denotes significance compared to cluster 3.  Protein data is shown as mean (and confidence intervals). Significance denotes p<0.05 but in many cases 
p<0.01 
Clusters 1 2 3 4 5 6 
II 93(92-95) +‡ 74(72-76) *‡ 108(100-115) *+ 83(81-86) *+‡ 66(63-69) *+‡ 38(32-43) *+‡ 
V 85(83-87) +‡ 66(63-69) *‡ 104(100-107) *+ 74(69-78) *‡ 41(37-45) *+‡ 20(15-25) *+‡ 
VIII 265(254-277) + 206(194-219) *‡ 263(246-280) + 372(343-401) *+‡ 206(186-225) *‡ 121(92-151) *+‡ 
VII 90(88-92) +‡ 74(71-77) *‡ 112(109-115) *+ 87(83-91) +‡ 83(79-87) *+‡ 44(38-50) *+‡ 
XI 105(102-107) +‡ 77(74-80) *‡ 115(112-119) *+ 110(103-118) +‡ 78(73-83) *‡ 38(31-45) *+‡ 
IX 115(112-118) +‡ 84(81-87) *‡ 125(122-129) *+ 120(111-128) +‡ 83(78-88) *‡ 45(37-52) *+‡ 
X 90(89-92) +‡ 71(69-74) *‡ 109(107-112) *+ 82(79-85) *+‡ 67(64-70) *+‡ 37(31-42) *+‡ 
XIII 115(112-118) + 99(95-103) * 116(112-120) + 107(95-120) *‡ 87(82-91) *+‡ 66(58-75) *+‡ 
Von Willebrand 
Antigen 
224(217-232) +‡ 192(181-203) * 195(186-204) * 348(329-367) *+‡ 293(277-309) *+‡ 217(179-255) ‡ 
Antithrombin 94(93-95) +‡ 70(68-73) *‡ 100(98-101) *+ 84(82-86) *+‡ 68(66-71) *‡ 39(34-45) *+‡ 
Protein C 102(101-104) + 77(75-79) *‡ 102(99-105) + 91(87-95) *+‡ 75(72-78) *‡ 48(41-56) *+‡ 








Figure 6.5 Coagulation factors 1 
All points are mean and confidence intervals. Significance data is given in the corresponding data 
tables 
 






















































































Figure 6.6 Coagulation factors 2 
All points are mean and confidence intervals. Significance data is given in the 
corresponding data tables 
 



















































The ROTEM data is summarised in table 6-5. The degree of derangement seen on ROTEM in 
some ways simply reflect the derangements see in the above 2 sections. 
There was a prolongation of the clotting time but only in the two most severely 
coagulopathic groups. And even though these groups were obviously coagulopathic by INR 
they were not definitely so by ROTEM based on our groups previous exploration of 
CA5(37). C5 was on the threshold of coagulopathy by ROTEM. C6 was coagulopathic by 
ROTEM but the variability in this group was much higher than others (figure 6.7).  Over all 
clot strength (MCF) was reduced compared to the ‘normal’ groups. 
The ExTEM maximum lysis in the two extreme groups was significantly raised. This would 
be expected given the biological data findings. It is interesting though that aporotinin was 
able to reverse the lysis over all such that the ApTEM maximum lysis no longer showed a 
significant lysis (figure 6.8) 
 
Figure 6.7 ExTEM parameters 
All points are mean and confidence intervals. Significance data is given in the corresponding 
data tables 
 




























































Table 6-5 ROTEM measures of Coagulopathy 
Significance testing between clusters. * denotes significant difference compared to cluster 1, + denotes significant difference compared to cluster 2 and 
‡ denotes significance compared to cluster 3.  ROTEM data is shown as mean (and confidence intervals). Significance denotes p<0.05 but in many cases 
p<0.01 
Clusters 1 2 3 4 5 6 
ExTEM 
Clotting time 59(57-61) 57(54-59) 63(60-67) 65(60-69) 116(65-167) *+‡ 132(69-194) *+‡ 
Clot Amplitude 5 min 45(44-46) 44(42-45) 45(44-46) 41(39-43) *‡ 36(34-38) *+‡ 34(28-39) *+‡ 
Alpha-angle (degrees) 72(71-73) 71(70-72) 72(71-73) 69(67-70) *‡ 65(64-67) *+‡ 65(59-71) *+‡ 
Maximum clot firmness 63(62-64) 62(61-63) 61(60-62) 59(57-60) *+‡ 56(54-58) *+‡ 52(45-59) *+‡ 
% Maximum lysis 8(7-9) 8(7-9) 8(7-8) 7(6-8) 19(13-25) *+‡ 22(4-39) *+‡ 
FibTEM 
Clot amplitude 5 min 13(13-14) 13(12-13) 13(13-14) 10(10-11) *+‡ 9(8-9) *+‡ 8(7-10) *+‡ 
Maximum clot firmness 16(15-17) 16(14-17) 16(15-17) 13(12-14) *+‡ 11(10-12) *+‡ 11(9-13) *+‡ 
ApTEM 
Clot amplitude 5 min 45(44-46) 43(41-44) 45(44-46) 40(38-42) *‡ 35(34-37) *+‡ 31(26-37) *+‡ 
Maximum clot firmness 62(61-63) 61(60-62) 61(60-62) 58(56-60) *+‡ 55(53-58) *+‡ 51(45-58) *+‡ 









Figure 6.8 Lysis seen on ROTEM 
All points are mean and confidence intervals. Significance data is given in the 
corresponding data tables 
 
















































6.3.5 Resuscitation fluids (RF) 
The fluids received in the first 24 hours are summarised in table 6-6 below. C3 received the 
lowest amount of RF over all further suggesting this is the most uninjured or normal group. 
C2 which had low injury load and not particularly deranged physiology still received a 
significant amount of blood and blood products (figure 6.9). 
C5 received the highest mean volumes of hypertonic saline. This also reinforces our earlier 
observations that this group had a significant number of head injuries. 
C6 was the cluster utilising the highest number of blood and blood products. If this group 
does indeed have a consumptive coagulopathy, this strategy may not have been conducive 
to resuscitation. This underlines the importance of early diagnosis and of this type of work. 
 
 
Figure 6.9 Ongoing Fluid Requirements 
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Table 6-6 Fluid Resuscitation 
Significance testing between clusters. * denotes significant difference compared to cluster 1, + denotes significant difference compared to cluster 2 and 
‡ denotes significance compared to cluster 3.  Fluid data is shown as mean (and confidence intervals). Significance denotes p<0.05 but in many cases 
p<0.01 
 
 1 2 3 4 5 6 
Crystalloid (mls) 1548(1359-1737) 1951(1417-2486) 1328(1119-1537) 2669(2318-3019) *+‡ 2781(2298-3265) *+‡ 2569(1776-3361) ‡ 
Colloid (mls) 254(190-319) 231(155-308) 163(103-223) 700(525-876) *+‡ 798(607-988) *+‡ 473(226-720) ‡ 
Packed red cells 0.72(0.53-0.91) 1.68(1.18-2.18) ‡ 0.3(0.16-0.44) + 2.62(1.92-3.32) *+‡ 5.58(4.54-6.62) *+‡ 8.06(5.77-10.35) *+‡ 
Fresh frozen plasma 0.34(0.21-0.46) 0.85(0.55-1.15) ‡ 0.15(0.05-0.26) + 1.6(1.08-2.12) *+‡ 3.35(2.63-4.07) *+‡ 6.03(3.81-8.25) *+‡ 
Platelets 0.08(0.05-0.12) 0.27(0.16-0.38) ‡ 0.03(0-0.06) + 0.29(0.17-0.41) *‡ 1(0.73-1.27) *+‡ 1.35(0.67-2.04) *+‡ 
Cryoprecipitate 0.03(0.01-0.06) 0.13(0.05-0.2) 0.01(0-0.03) 0.32(0.16-0.48) *+‡ 0.63(0.43-0.82) *+‡ 0.41(0.03-0.8) *‡ 





Outcomes for all groups are shown in table 6-7 below. The outcomes for C1-3 were overall 
better than the other groups as one might expect. Groups C4-6 had gradually worse 
outcomes respectively over all. What is surprising however, is the relatively low mortality 
rate in C6. Given the extremes of coagulation derangement one might expect the mortality 
to be much higher than it was. The fact that the highest mortality was in C5 (and not C6) 
(figure 6.10) may again reflect the degree of head injuries seen in that group. 
C4-6 also had worse critical care, vasopressor and ventilator days suggesting overall more 
organ and possibly multi-organ dysfunction. 
 
 
Figure 6.10 Outcomes 
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Table 6-7 Outcome measures 
Significance testing between clusters. * denotes significant difference compared to cluster 1, + denotes significant difference compared to cluster 2 and 
‡ denotes significance compared to cluster 3.  Mortality is shown and mean and confidence intervals. All other outcome data is given at median and 
interquartile range. Significance denotes p<0.05 but in many cases p<0.01 
 
Clusters 1 2 3 4 5 6 
Mortality % 3(2-5) 9(6-13) 2(0-4) 14(9-20) *‡ 51(43-59) *+‡ 29(13-46) *+‡ 
Critical care days 3(3-4) ‡ 4(3-5) ‡ 2(1-2) *+ 6(5-8) *+‡ 7(6-9) *+‡ 12(7-16) *+‡ 
Vasopressor days 1(1-1) 1(0-1) 0(0-1) 2(1-2) *+‡ 2(2-3) *+‡ 4(0-7) ‡ 
Renal replacement therapy 0(0-0) 0(0-0) 0(0-0) 0(0-0) 0(0-1) *‡ 0(0-0) 
Ventilator days 2(1-2) 2(1-3) ‡ 1(0-1) + 4(3-6) *+‡ 5(4-6) *+‡ 6(3-10) *+‡ 







Understanding and interpreting the coagulation system derangements in trauma continues 
to be a challenge. But with more robust data collection and with analysis techniques 
borrowed from other disciplines progress can be made. 
With this work we have primarily shown that it is possible to use a hierarchical clustering 
on a medium sized protein dataset to classify derangements in an unbiased way. We have 
shown that the results obtained are meaningful and do seem to correlate with previous 
results on this important disease process. We have shown this can be done in an unbiased 
way and has therefore potential to discover unexpected groups (such as C6).  
Other teams have used clustering in trauma coagulation research.  The Pittsburgh group 
have used it on an animal model with relatively small numbers(86). White and colleagues 
have applied it to their human dataset(87). This has shown meaningful results but again 
those are relatively small numbers. The utility of clustering small groups is not immediately 
obvious. To our knowledge this current work represents the largest human dataset in 
trauma for this type of analysis to date.  
This method has been useful in understanding the patterns of derangement without a 
priori assumptions or bias. Hierarchical clustering has identified 6 different groups. One of 
these (C3), is likely to represent minimally injured patients with very few (if any) 
physiological sequelae. Even in this group, levels of coagulation proteins were abnormal in 
comparison to their reference ranges. PAP, tPA, PT1+2 and D-dimer were raised, suggesting 
a level of activation of the coagulation system. 
The remaining clusters are all at different levels of activation, likely all of the fibrinolytic 
system as we see PAP and D-dimer going higher as we go from C1 to C2, C4, and C5. C5 is 
the group with the most severe form of fibrinolysis. The difference between this and other 
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clusters is mainly the presence of the significant head injuries in this group. It has long been 
thought that head injuries are a contributing factor to development of hyperfibrinolysis. 
Certainly there is a strong association between coagulopathy and head injury(88). Our data 
support this conclusion. But they possibly go further. We have shown how severe a 
derangement there actually is. Along with the extreme rise in PAP and D-dimer there is also 
a relative decrease in the numbered clotting factors. All this together may contribute to the 
significant functional coagulopathy in these patients. The other striking feature is how 
quickly this coagulopathy develops. Cluster C5 had a scene to hospital time of about 1 hour 
and 15 minutes. Part of the CRASH-2 trial findings was to give TXA as quickly as possible 
after injury. The aim of the CRASH-3 trial is similar but the cut-off to give the drug is 8 
hours. With such a significant coagulopathy developing so quickly it simply underlines the 
need for early intervention. It also adds weight to the argument that TXA should be given 
on much earlier timescales than this to avoid secondary bleeds and exacerbation of brain 
injury. 
A further important finding is that of Cluster 6. This is a small part of the patient cohort. 
This group has only 34 patients out of 1229 analysed, i.e. 2.76%. Nevertheless it is an 
important group because it displays a separate mechanism of coagulopathy. This severe 
coagulopathy appears to have signs of a consumption and not pure fibrinolysis alone. The 
finding of the high SFMC is key to this discussion. Soluble Fibrin Monomer complexes are a 
part of the diagnostic criteria to diagnose DIC as defined by the International Society of 
Thrombosis and Haemostasis (ISTH)(89,90). However, with platelet levels being maintained 
this draws into question whether this can truly be DIC or not. Certainly other groups, 
particularly the Japanese critical care fraternity, have been strong advocates of DIC being 
the main coagulopathy in trauma for some time(91,92). But our observations show a small 
group in a much larger cohort that does not display DIC as a whole.  
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Why these patients should develop a consumptive coagulopathy should also be 
questioned. Certainly they have a high injury load (ISS-29) but don’t have as many head 
injuries as C5. The rate of penetrating injury is highest in this group also. Meaning, this 
could be a group with direct vascular injury and massive early blood loss. Certainly they 
have utilised the most prehospital IV fluids and blood products. Even in the first 24 hours of 
admission they continue to use blood and products more than the other groups. What is 
certainly curious is the relatively low mortality in this group (29% vs 51% for C5) given the 
severity of coagulation derangement; again, suggesting that perhaps acute vascular bleeds 





  Chapter 7
7.1 Summary of findings 
The main focus of this body of work has been to understand the mechanisms behind the 
acute coagulopathy of trauma.  Chapter three has described the incidence of fibrinolytic 
activation in trauma patients. Although there had been previous studies to understand the 
fibrinolytic component of coagulopathy, interest was renewed since the publication of the 
CRASH-2 trial. Our description of the incidence of activation and the magnitude of 
derangement has gone some way to explaining why a pragmatic approach to treating 
fibrinolysis in trauma should be successful. In doing so we have described the scale of a 
problem which had, until now, not been fully appreciated. There are advocates who 
suggest treatment of fibrinolysis should only be undertaken with viscoelastic test evidence. 
We have demonstrated that fibrinolytic activation is largely undetectable by 
thromboelastometry (apart for the most severe cases) and even moderate FA confers a 
significant risk of mortality and morbidity which cannot be ignored. This coupled with the 
scale of fibrinolytic activation adds weight to the evidence for use of antifibrinolytics in 
trauma as an agent in pts with a risk of blood loss.  
Explaining the specific mechanisms is more difficult. Chapter 4 has attempted to 
understand the role of three specific factors which have been implicated in the modulation 
of fibrinolysis. We have shown that PAI-1 may well have an influence on the level of FA 
irrespective of the influence of tPA on promoting lysis. This could clearly be a possible locus 
for molecular intervention. 
FXI has been implicated in the curtailing of fibrinolysis. We have shown that at maintained 
levels this is unlikely the case, but depletion of FXI may well be associated with fibrinolysis. 
This mechanism has previously been postulated to work through thrombin generation and 
TAFI. We have however also demonstrated that circulating plasma TAFI does not seem to 
have any influence on fibrinolysis curtailment. This does not speak of the TAFI that may 
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exert effect form a platelet source. This work would be much more challenging but may 
well be required if the mechanism is to be better understood. 
The final section is perhaps the most exciting. Of course for its findings, but also due to the 
potential that it may afford. In this work we have developed a technique commonly used in 
other fields to analyse large amounts of data which would be otherwise difficult. In doing 
so we have shown that this is a relevant technique in current analyses. Its findings are to 
some extent validation of the process and function of the method. Our aim was to examine 
this dataset in an unbiased manner and we have achieved that. In doing so a possibly 
important coagulopathy has been described. It may only make up a small percentage of 
cases but had we used conventional techniques to analyse such a large dataset perhaps we 
would not have shown this derangement. 
The most important clinical or biological finding of this section of work is to show that 
fibrinolysis is the overriding coagulopathy in trauma. Over the years various mechanisms 
have been postulated and supported. The 3 main current prevailing theories come from 
various groups; our group in London (under Professor Brohi), the Japanese group (under 
Professor Gando) and the Denver group (under EE Moore). The London group has long 
been an advocate for the primary fibrinolysis mechanism likely mediated by aPC (30). The 
Japanese group has advocated DIC as a mechanism for many years and more recently this 
has been re-described as DIC with fibrinolytic phenotype(91). The Denver group have 
advocated a theory based on fibrinolysis shutdown (93) They have also been cautious in 
recommending early use of antifibrinolytics without diagnosis beforehand (94). 
The findings of this current body of work would support primary fibrinolysis being the 
predominant mechanism. In fact we have found no evidence that at admission either DIC 
or fibrinolysis shutdown are relevant mechanisms. Moreover, the assertion by the Denver 
group that antifibrinolytics should be withheld until a diagnosis of fibrinolysis is 
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questionable given that we have shown the almost ubiquitous activation of fibrinolysis in 
all but the least injured patients. In addition as in previous chapters we have shown the 
early biochemical markers of fibrinolysis with absence of lab or point of care markers. 
Delaying use of antifibrinolytics in this context could be potentially dangerous. 
The theory of fibrinolysis shutdown is largely based on TEG analysis, and to date, is not 
backed up by laboratory protein data. This may be questionable since we have already 
shown that ex-vivo viscoelastic tests may not be sensitive at detecting fibrinolysis. One of 
the strengths of this work is therefore the protein level analysis revealing fibrinolysis and 
not fibrinolysis shutdown or DIC.   
The analysis does show the main derangement of coagulation to be fibrinolysis and shows 
again how even moderate levels of injury can result in FA, mirroring the findings of chapter 
3. To reiterate; hierarchical clustering has not demonstrated any other major coagulopathy. 
Therefore we would suggest that fibrinolysis is likely the main and certainly the most 
clinically important coagulopathy found on admission in major trauma.    
7.2 Strengths and weaknesses of this work 
 
To our knowledge, this is the largest non-pragmatic prospective study of trauma 
coagulation to date. Very large trauma registries exist but have issues retrospectively 
analysing data. For one, if a clinical question needs to be answered and he material 
collected is inadequate, retrospective analysis will not work. When data is collected 
prospectively (as we have done here) we are able to capture much more information that is 
useful and relevant. But this also creates issues for analysing such large datasets. We 
therefore need to leverage modern data analysis techniques. Our technique may not be 
perfect and even primitive in comparison to gene expression and modern mathematical 
techniques. But we have taken this step with the intention to move forward in this field. 
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My colleagues Zane Perkins and Simon Glasgow are involved in similar projects. One is 
using Bayesian network prediction tools to predict outcomes on an individual level and the 
other; an agent based modelling environment to predict population and public health 
requirements in major trauma incidents. This is exciting time moving forward and we are 
privileged to contribute to this. This work has also meant close relationships with computer 
science and mathematics departments across our university site. These are relationships 
that our group will continue to benefit from. 
The novelty of this work specifically is that we have repurposed old techniques in other 
sciences to good effect on the largest cohort of trauma subjects recruited to date. 
Over the past few years of recruiting patients in an accident an emergency environment 
using the PLAR consent process we have been very successful indeed. There has been a 
very low rate of patients who were not able to consent or withdrew consent after the 
process. This shows that this type of research can be performed in the emergency setting. 
This has reaped benefits on a local and international level. There is now an ED research 
team that started recruiting to their own trials at times using our expertise from ACITII. Our 
encouragement and guidance of their research practise has been instrumental in this 
process. Our collaboration with European centres has flourished. Fellows from their centres 
have regularly visited us to take on board our practice in their own countries. Through this 
collaboration we have increased the recruitment to our own study. 
Our constant presence in the ED and our use of ROTEM has meant that ED has now 
acquired their own ROTEM machine which can be used for any patient. This was a direct 
result of our familiarity with this research tool and our support in clinical practice. 
Data collection from this type of patient group has been challenging at times. Patients in 
extremis do not lend themselves well to having blood taken continuously or regularly. This 
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has led to gaps in our data at times. We have worked very hard to reduce this data loss. A 
result of this can be seen in the final chapters where a significant number of subjects had to 
be excluded due to missing data. This is almost always a result of deterioration of a very 
small sample or from continuous processing of the same sample for so many tests. In 
future it may be possible to gain all this information from minute samples of blood on to 
protein detection chips. Until then we may continue to suffer from missing data. 
 It is also important to note that much of the work above and through ACITII is 
observational work. It results in conclusions that can be at best associations and 
correlations. This is still an important part of practice but the observations we make and 
conclusions we derive must be tested in a clinical interventional or in a in vivo non-human 
setting.  There are other members of our group who continue to do this. 
One major disappointment was the difficulty with the TM ELISA. Had this ELISA not 
changed we may have been able to include much of the TM data which would undoubtedly 
help in understanding these mechanisms further. 
7.3 Future work 
This current work is a limited view of coagulopathy. It is limited by virtue of being data 
collected only on the patient’s admission. We currently don’t have a significant idea of the 
natural history of coagulopathy over time and how our current interventions affect it. Some 
work has been carried out on bleeding patients but as yet we don’t have full datasets on 24 
hour and 72 hour time point samples. If we are able to study those time points also it will 
surely give us a fuller understanding. This would of course introduce many more variables, 
including time variables, but our use of clustering would enable those datasets to be 
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